March 2015 YOU AGM Newsletter

Northeastern Section AUA
6 1ST A N N U A L M E E T I N G
Scientific
Program
Visit us at
Facebook.com
and search for Northeastern Section
Connect with Other Attendees
View Scheduled Events
Post Discussions
NS-AUA 2009
Annual Meeting
CONTENTS
Welcome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .2
Needs Assessment and Learning Objectives . . . . . .4
CME Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5
Meeting-at-a-Glance . . . . . . . . . . . . . . . . . . . . . . . . . .6
Schedule-at-a-Glance . . . . . . . . . . . . . . . . . . . . . . . . .7
Officers and Committees Listing . . . . . . . . . . . . . . . . .10
Research Education Fund/Supporter Recognition . .11
Past Presidents and Meeting Venues . . . . . . . . . . . . .12
George E. Slotkin Lecturers . . . . . . . . . . . . . . . . . . . . .13
Invited Speakers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .14
Scientific Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . .18
Social Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .31
Quick Guide to Montreal . . . . . . . . . . . . . . . . . . . . . . .35
Exhibitor Listing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .37
Exhibitor by Booth Number / Exhibit Floor Plan . . . .41
Disclosure Information . . . . . . . . . . . . . . . . . . . . . . . . .42
CME Credit Form . . . . . . . . . . . . . . . . . . . . . . . . . . . . .43
PROG RAM
COM M ITTEE
Pierre I. Karakiewicz, Chair
Serge Carrier
Peter Chan
Bruno Laroche
Armondo J. Lorenzo
Dawn MacLellan
Robert K. Nam
D. Robert Siemens
Martine Jolivet Tremblay
Alexandre R. Zlotta
ARRANG EM ENTS
COM M ITTEE
Julie Franc-Guimond, Co-Chair
Paul Perrotte, Co-Chair
Juan Diego Barrieras
Serge Carrier
I NVITED S PEAKERS
George E.
Slotkin Lecture
Sir. Philip G.
Ransley
Gerald B. Brock
Martine Jolivet-Tremblay
Eric A. Klein
John M. Fitzpatrick
Edward M. Messing
Robert M. Moldwin
Francesco Montorsi
J. Curtis Nickel
Shahrokh F. Shariat
1
NS-AUA 2009 Annual Meeting
Dear Colleagues and Friends,
It is my honor to invite you to the 61st Annual Meeting of the Northeastern Section of the
American Urological Association (NS-AUA). Nearly twenty years ago I attended my first
NS-AUA meeting at the encouragement of my mentor, Dr. B.M. Churchill. I believe this
sectional meeting is a unique occasion to share Canadian perspectives and experiences
with our American colleagues. It gives us a distinct opportunity to discuss controversial
issues and novelties with renowned experts in a somewhat “intimate” setting. Coupling a
state-of-the-art scientific program with the inimitable backdrop of the beautiful and historic Montréal, this year’s Annual Meeting is sure to be a success.
Dr. Pierre Karakiewicz, Program Chair, and his team have organized an exciting educational program including
distinguished expert speakers, point-counterpoint debates and clinically relevant plenary sessions to ensure an
exceptional educational value of the meeting. Hot topics to be discussed at the plenary sessions include: Erectile
Dysfunction after Radical Prostatectomy; Stress Urinary Incontinence and Unstable Bladder; Prostate Cancer and
Chemo Prevention; Locally Advanced and Metastatic Kidney Cancer; Kidney Cancer and Androgen Deprivation
Therapy; Prostatitis, Benign Prostatic Hyperplasia and Unstable Bladder. Invited speakers include: Sir Philip Ransley, MD, the George F. Slotkin Lecturer; Gerald Brock, MD; Martine Jolivet-Tremblay, MD; Eric A. Klein, MD; John
Fitzpatrick, MD; Edward Messing, MD; Robert M. Moldwin, MD; Francesco Montorsi, MD; J. Curtis Nickel, MD
and Shahrokh Shariat, MD. We are also very excited to once again feature a one-day Nursing Program on Friday,
October 9, 2009.
Drs. Paul Perrotte and Julie Franc-Guimond have organized a fun-filled social program highlighting many of Montréal’s unique cultural offerings. Join us for a night at the circus on Friday for the Fun Night event at Cirque Éloize!
The renowned Cirque Éloize training center, located in Old Montréal, will be the setting for our cocktail reception
and dinner for this incredible night of entertainment. Guests can take advantage of the Botanical Garden, Insectarium and Biodôme tour on Friday as well at the Old Montréal Historical Tour on Saturday. The closing banquet
on Saturday night will feature Dr. Richard Béliveau, researcher and author of three books on nutrition and cancer.
Dr. Béliveau and the hotel chef have designed an exquisite menu for this event that coincides with Dr. Béliveau’s
cancer-fighting research
On behalf of the entire organizing committee, I look forward to seeing you in Montréal!
Anne-Marie Houle
President, Northeastern Section of the AUA
2
Northeastern Section of the AUA — 2009 Annual Meeting
Chers(ères) Collègues et Amis(es),
C’est avec beaucoup d’enthousiasme que je vous invite chaleureusement à participer au 61ième Congrès Annuel
de la section Northeastern de l’Association Américaine d’Urologie (NS-AUA). Il y a déjà 20 ans, à la suggestion
de mon mentor le Dr. BM Churchill, j’assistais à mon premier congrès de la section. J’ai alors découvert un forum
unique pour partager et discuter des perceptives et expériences canadiennes distinctives avec nos collègues
américains. Le congrès offre aussi une occasion peu commune de débattre des sujets les plus chauds et controversés et d’être initié aux plus récents développements en urologie avec un accès privilégié aux experts reconnus
dans ces domaines. Avec la vie socio-culturelle trépidante de Montréal en toile de fond et un programme scientifique à la fine pointe, le congrès annuel de 2009 promet d’être un évènement à ne pas manquer.
Dr. Pierre Karakiewicz, Directeur Scientifique du Congrès, et son équipe, ont déjà confirmé une brochette de conférenciers exceptionnels et développé un programme éducationnel interactif excitant incluant débats, panels et
plénières. La dysfonction érectile post prostatectomie radicale, l’incontinence urinaire et l’hyperactivité vésicale, la
chimio prévention du cancer de la prostate, le cancer du rein localement avancé ou métastatique, la prostadynie
et le syndrome de douleur pelvienne constituent les sujets chauds qui se partageront la vedette. La liste de nos
conférenciers invités est des plus impressionnantes avec Sir Philip Ransley, MD, le conférencier George F. Slotkin;
Gerald Brock, MD; Martine Jolivet-Tremblay, MD; Eric A. Klein, MD; John Fitzpatrick, MD; Edward Messing, MD;
Robert M. Moldwin, MD; Francesco Montorsi, MD; J. Curtis Nickel, MD and Shahrokh Shariat, MD. Cette année
sera aussi marquée par la deuxième édition d’un programme distinct d’une journée spécialement conçu pour les
infirmiers et infirmières en urologie du territoire de la section qui se tiendra le 9 octobre 2009.
Les Drs. Paul Perrotte and Julie Franc-Guimond ont mis sur pied un programme d’activités sociales mettant en
valeur les principaux atouts de Montréal. La soirée de bienvenue au Fairmont Reine Élisabeth soulignera l’engagement de Montréal pour notre sport national, le hockey, avec des activités appropriées et des surprises de
taille. Vendredi soir, nous célèbrerons nos artistes de cirque avec le Cirque Éloize qui nous accueillera dans ses
installations d’entraînement dans le Vieux Montréal et qui se produira au cours de la soirée. Durant la journée, les
accompagnants pourront profiter de visites guidées du Jardin Botanique, de l’Insectarium et du Biodôme vendredi et du Vieux Montréal, samedi. Le banquet de clôture aura lieu dans la salle de bal du Reine Élisabeth et
mettra en vedette le Dr. Richard Béliveau, chercheur et auteur réputé dans le domaine de la nutrition et la
prévention du cancer. Le chef exécutif du Fairmont et le Dr. Béliveau uniront leurs savoirs et savoir-faire pour
nous concocter un menu aussi raffiné et exquis que santé.
Au nom de tout le comité organisateur, je vous invite à vous joindre à nous à Montréal du 7 au 11 octobre 2009
pour le Congrès annuel de la NS-AUA. Nous vous attendons en grand nombre.
Anne-Marie Houle
Président, Northeastern Section of the AUA
3
N EEDS AS S ES S M ENT
The field of urology is in constant evolution and established practices need to be periodically updated. This
year’s Annual Meeting will provide participating urologists with several such updates. The topics will focus
on urologic malignancies (e.g., prostate, bladder and
renal cancers), as well as non-malignant pathologies
(e.g., benign prostatic hypertrophy, urinary incontinence, prostatitis, overactive bladder and hypogonadism). Urologic malignancies contribute to a
significant proportion of urologic referrals. In the past
decade the treatment algorithms have changed for patients with renal cancer. Patients with small renal
masses may benefit from multiple treatment alternatives, which range from surgery to surveillance. Patients with unresectable or metastatic renal cancer can
now benefit from an array of systemic therapies. The
urologist needs to play a central role, as cytoreductive
nephrectomy and metastasectomy remain key management components for such patients and their timing is crucial. In the field of prostate cancer, several
paradigms have changed. For example, controversy exists regarding screening. Novel preventive modalities
will soon be introduced. Finally, the long-term risks and
benefits of androgen ablation therapy affect the timing,
the duration and the patterns of administration of this
treatment modality. In bladder cancer several therapeutic alternatives exist for patients with non-muscle
invasive high risk disease. These issues will be addressed in the program.
Despite the importance of urologic malignancies, the
bulk of urologic referrals are for non-malignant pathology. Prostatitis, benign prostatic hypertrophy, overactive bladder, hypogonadism and erectile dysfunction
represent some of many common urologic complaints.
Despite their apparent simplicity, the investigation
and/or management of these conditions may represent
a challenge. Moreover, novel pharmacological management options have multiplied for several of these
conditions. For example, the number of medical management options for overactive bladder has increased
exponentially. Conversely, effective treatment options
for patients with prostatitis remain scarce.
To address the diagnosis and management of these
urologic conditions, the 2009 NS-AUA Annual Meeting
will feature a total of 10 presentations that will be complemented by an equal number of expert panels and
additional point-counterpoint sessions. Eight poster
sessions will cover these areas with expert moderated
discussions around the presented topics. Overall, the
state-of-the-art lectures, podium and poster sessions
presented by many North American and European experts promise to deliver excellent educational value.
The meeting will offer up to 18.75 AMA PRA Category
1 Credits™.
LEARN I NG OBJ ECTIVES
At the conclusion of the 2009 NS-AUA Annual Meeting, participants should be able to:
I interpret and evaluate the existing evidence in favor
and against prostate cancer screening
I critically appraise the data on available chemoprevention therapies for prostate cancer
I weigh the pros and cons of early vs. delayed androgen deprivation therapy and critically appraise the
value of continuous vs. intermittent therapy
I critically appraise the risks and benefits of intravesicle therapy relative to early cystectomy for non-muscle invasive high risk bladder cancer patients
I gain a thorough understanding of medical management of overactive bladder
I obtain an update of available management options
and their efficacy for patients with chronic prostatitis
I review the magnitude of urologic risks associated
with testosterone supplementation
I examine the value of available treatment regimens
for erectile dysfunction in the aging male, as well as
after urologic surgery
I reassess the central role of the urologist in the management of surgically unresectable and metastatic
renal cancer, and become familiar with the existing
molecules for the management of unresectable
and/or metastatic renal cell carcinoma and with the
common toxicities
4
Northeastern Section of the AUA — 2009 Annual Meeting
C O N T I N U I N G M E D I CA L E D U CAT I O N
Accreditation: The American Urological Association
(AUA) is accredited by the Accreditation Council for
Continuing Medical Education (ACCME) to provide
continuing medical education for physicians.
The AUA takes responsibility for the content, quality
and scientific integrity of this continuing medical education (CME) activity.
Credit Designation: The AUA designates this educa-
tional activity for a maximum of 18.75 AMA PRA Category 1 Credits™ . Physicians should only claim credit
commensurate with the extent of their participation in
the activity.
provide members of the audience with information on
which they can make their own judgments.
Unlabeled or Unapproved Use of Drugs or Devices:
It is the policy of the AUA to require the disclosure of
all references to unlabeled or unapproved uses of
drugs or devices prior to the presentation of educational content. The audience is advised that this CME
activity may contain reference(s) to unlabeled or unapproved uses of drugs or devices. Please consult the
prescribing information for full disclosure of approved
uses.
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose
input is included in this program are their own and do
not necessarily represent the viewpoint of the AUA.
AUA Disclosure Policy: As a provider accredited by
the ACCME, the AUA must insure balance, independence, objectivity and scientific rigor in all its activities.
All faculty participating in an educational activity provided by the AUA are required to disclose to the
provider any relevant financial relationships with any
commercial interest. The AUA must determine if the
faculty’s relationships may influence the educational
content with regard to exposition or conclusion and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this
disclosure is not to prevent faculty with relevant financial relationships from serving as faculty, but rather to
Evidence-Based Content: As a provider of CME accredited by the ACCME, it is the policy of the AUA to
review and certify that the content contained in this
CME activity is valid, fair, balanced, scientifically rigorous and free of commercial bias.
Special Assistance/Dietary Needs: The AUA, an organization accredited for CME, complies with the
Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary
restrictions, a written request should be submitted at
least one month in advance. For additional assistance
with your request please call 410-689-4025.
5
Meeting at-a-Glance
TH U RS DAY, OCTOB ER 8, 2009
I Plenary/Guest
Lectures: ED, Kidney Cancer, Testosterone Supplementation, Prostatitis, BPH and Unstable
Bladder
I Moderated Poster Session: Prostate Cancer, Basic Research, Robotics, Endoscopy and Laparoscopy, and
Bladder Cancer
I Sneak Peek Luncheon in Exhibit Hall
I Exhibit Hall Grand Opening/Welcome Reception
I Networking Reception
FRI DAY, OCTOB ER 9, 2009
I 5K
Fun Run/Walk
Tour of Botanical Gardens, Insectarium & Biodome
I Industry-sponsored Breakfast Symposium Sponsored by VIVUS, Inc.
I Prize-Winning Essays
I Nursing Program
I Plenary/Guest Lectures: Prize-Winning Essays, PSA Screening, Prostate Cancer Chemoprevention
I AUA Course of Choice
I Moderator Poster Sessions: Pediatric Urology, Oncology, General Urology and Kidney Cancer
I Exhibit Hall Open
I Fun Night at Cirque Éloize
I Spouse
SATU RDAY, OCTOB ER 10, 2009
I Industry-sponsored
Breakfast Symposium Sponsored by Ferring Pharmaceuticals
I Residents
Program
Business Meeting
I Plenary/Guest Lectures: Pediatric Urology, Androgen Deprivation Therapy, Stress Urinary
Incontinence and Unstable Bladder
I George F. Slotkin Lecture
I Tennis Tournament
I Tour of Old Montréal
I President’s Reception & Banquet
I Annual
EXH I B IT HALL HOU RS
Thursday, October 8
Friday, October 9
Noon – 3:30 p.m.
5:30 – 6:30 p.m.
9:30 a.m. – 1:30 p.m.
6
Northeastern Section of the AUA — 2009 Annual Meeting
S C H E D U L E - AT- A - G L A N C E
Thursd ay, O ct obe r 8 , 20 0 9
Plenary
Marquette/Jolliet
Time
Mackenzie
Duluth
Hochelaga 1-6
7 a.m.
7:30 - 9:45 a.m.
8 a.m.
Plenary I: ED after Radical
Prostatectomy - Francesco Montorsi,
Gerald Brock and Panel
Locally Advanced & Metastatic RRC
- John Fitzpatrick, Pierre Karakiewicz
and Panel
9 a.m.
9:45 - 10:15 a.m.
Break
10 a.m.
11 a.m.
10:15 a.m. - Noon
10:15 a.m. - Noon
Moderated Poster Session I
Moderated Poster Session II
Postate Cancer
Basic Research
Noon - 1:30 p.m.
Noon
Sneak Peek Luncheon
Exhibit Hall
1 p.m.
1:30 - 2:45 p.m.
Plenary II: Testosterone
Supplementation and Its Risks Panel
Exhibit Hall Open
Prostatitis: A phoenix Rising from
the Ashes - J. Curtis Nickel and Panel
Hoch 1-6, Saguenay &
St. Maurice
2 p.m.
1:30 - 3:30 p.m.
2:45 - 3:15 p.m. Break in Exhibit Hall
3 p.m.
4 p.m.
3:15 - 5 p.m.
3:15 - 5 p.m.
Moderated Poster Session III
Moderated Poster Session IV
Robotics, Endoscopy, and
Laparoscopy
Bladder Cancer
5 p.m.
5:30 - 6:30 p.m. Exhibit Hall Grand Opening/Welcome Reception
6 p.m.
7 p.m.
7 - 9 p.m. Networking Reception (St. Laurent)
8 p.m.
Registration Open: 7 a.m. - 5 p.m.
Speaker Ready Room Open: 7 a.m. - 6 p.m. (Saint-Charles Room)
Spouse Lounge Open: 7 - 9 a.m. (Suite 1742-John Lennon/Yoko Ono Suite)
Events
Plenary
Exhibit Hall
Poster Sessions
Breaks
Meetings/Nursing Program
Industry Supported Breakfast
7
S C H E D U L E - AT- A - G L A N C E
Frid ay, Oc t ob e r 9 , 20 0 9
Time/
Room
Plenary
Marquette/Jolliet
Mackenzie
6 - 7:30 a.m.
Industry Supported
Breakfast - The Post
Prostatectomy Bridge:
Tissue Preservation after
Radical Pelvic Surgery,
Suported by Vivus, Inc.
6 a.m.
7 a.m.
Richelieu
7:45 - 8:45 a.m.
Plenary Session III:
Section Stars
9 a.m.
8:45 - 9:45 a.m.
Plenary Session IV:
Prostate Cancer Screening Eric A. Klein, Francesco Montorsi
and Panel
9:45 - 10:15 a.m.
Break in Exhibit Hall
10 a.m.
11 a.m.
Noon
2 p.m.
66:30 - 8 a.m.
5K Run for Residents
7:30 - 7:45 a.m.
Best-of-Posters
(from Thursday sessions)
8 a.m.
1 p.m.
Saint
Laurent/Gatineau
Duluth
10:15 a.m. - Noon
10:15 a.m. - Noon
Moderated Poster
Session V
Moderated Poster
Session VI
Pediatric Urology
Oncology
9:30 a.m. - 1:30 p.m.
Exhibit Hall Open
Hoch 1-6, Saguenay
& St. Maurice
7:30 a.m. - 4 p.m.
Nursing Program
(See page 30)
Noon - 1:15 p.m.
Lunch in Exhibit Hall
1:15 - 2:15 p.m.
Plenary Session V:
Prostate Cancer Chemoprevention - Eric A. Klein and Panel
2:15 - 3:15 p.m.
AUA Course of Choice
Interstitial Cystitis/Painful Bladder Syndrome and Related
Conditions: Practical Management Strategies Robert Moldwin
3:15 - 3:30 p.m.
PM Break
3 p.m.
5 p.m.
3:30 - 5 p.m.
Moderated Poster
Session VII
3:30 - 5 p.m.
Moderated Poster
Session VIII
5:30 - 6:30 p.m.
General Urology
Kidney Cancer
Residents Reception
7 p.m.
7 - 10 p.m. Fun Night at Cirque Éloize
10 p.m.
8
Events
Plenary
Exhibit Hall
Poster Sessions
Breaks
Meetings/Nursing Program
Industry Supported Breakfast
Northeastern Section of the AUA — 2009 Annual Meeting
S C H E D U L E - AT- A - G L A N C E
S atu rday, Oc tober 10, 20 0 9
Plenary
Marquette/Jolliet
Time
Richelieu
Harricana
6 - 7:30 a.m. Industry Breakfast
Program – Revisiting Testosterone
Levels Achieved with Androgen Ablation:
What is Optimum Suppression?
6 a.m.
Supported by Ferring Pharmaceuticals
7 a.m.
8 a.m.
7:30 - 8:30 a.m.
7:30 - 8:30 a.m. Residents Breakfast - How
to Select a Urology Fellowship Program
Business Meeting
Shahrokh Shariat
8:30 - 8:45 a.m. Best-of-Posters
(from Friday sessions)
8:45 - 9:30 a.m.
Slotkin Lecture
Sir Philip Ransley
9 a.m.
9:30 - 10:15 a.m.
Plenary Session VI: Androgen Deprivation
Therapy - Edward Messing, Pierre Karakiewicz and
Panel
10 a.m.
10:15 - 10:45 a.m.
Break in Exhibit Hall
10:45 a.m. - 11:20 p.m.
Plenary VII: Pediatric Urology Sir Philip Ransley
11 a.m.
11:20 a.m. - Noon
Stress Urinary Incontinence and Unstable Bladder
- Martine Jolivet-Tremblay and Panel
Noon - Meeting adjourns,
box lunches available
Noon
12:30 p.m. Tennis
12:30 p.m. Tour of Old Montréal
6:30 p.m.
6:30 - 7 p.m.
President’s Reception
10 p.m.
7 - 10 p.m.
President’s Banquet
Events
Plenary
Exhibit Hall
Poster Sessions
Breaks
Meetings/Nursing Program
Industry Supported Breakfast
Speaker Ready Room Saint Charles Room
Hours of Availability:
Thursday, October 8: 7 a.m. – 6 p.m.
Friday, October 9: 7 a.m. – 6 p.m.
Saturday, October 10: 7 a.m. – Noon
9
NORTH EASTERN S ECTION BOARD OF DI RECTORS
2008-2009
President
Anne-Marie Houle, MD
Montreal, Quebec
President-Elect
Joel B. Nelson, MD
Pittsburgh, Pennsylvania
Past President
James W. L. Wilson, MD
Kingston, Ontario
Secretary
Edward M. Messing, MD
Rochester, New York
Treasurer
Hassan Razvi, MD
London, Ontario
Historian
Jack Sales, MD
Grand Bend, Ontario
Representatives
Young Urologist Members
Canada
J. Paul Whelan, MD
Hamilton, Ontario
New York
Imad S. Nsouli, MD
Syracuse, New York
Pennsylvania
Ronald L. Hrebinko, MD
Pittsburgh, Pennsylvania
At-Large - Canada
Armen G. Aprekian, MD
Montreal, Quebec
At-Large - US
Badar Mian, MD
Albany, New York
Canada
Kenneth T. Pace, MD
Toronto, Ontario
United States
Timothy D. Averch, MD
Pittsburgh, Pennsylvania
AUA Board of Directors
Kevin Pranikoff, MD
Eggertsville, New York
2008-2009 N S-AUA COM M ITTEES
Arrangements Committee
Diego Barrieras, MD
Serge Carrier, MD
Julie Franc Guimond, MD, Co-Chair
Paul Perrotte, MD, Co-Chair
Health Policy Committee
Ronald Paul Kaufman, Jr., MD
Robert Alan Mevorach, MD
Allan Beatteay Patrick , MD
J. Paul Whelan, MD, Chair
Awards Committee
Anne-Marie Houle, MD
Kevin Pranikoff , MD
James W.L. Wilson, MD, Chair
Investment Committee
Mark F. Bellinger, MD
Joseph L. Chin, MD
Anne-Marie Houle, MD
Hassan Razvi, MD, Treasurer, Chair
Bylaws Committee
Gabriel P. Haas, MD
Ron Kodama, MD
Edward M. Messing, MD, Chair
Development Committee
David A. Corral, MD
Joseph M. Greco, MD, Co-Chair
David B. Patrick, MD
J. Paul Whelan, MD, Co-Chair
Judicial Committee
R. Brewer Auld, MD
Gabriel P. Haas, MD, Chair
Kevin Pranikoff , MD
Program Committee
Serge Carrier, MD
Peter Chan, MD
Pierre Karakiewicz, MD, Chair
Bruno Laroche, MD
Armondo Lorenzo, MD
Dawn McLellan, MD
Robert Nam, MD
D. Robert Siemens, MD
Martine Jolivet Tremblay, MD
Alexandre Zlotta, MD
Scholarship Committee
Darius Jehan Bagli, MD
Erdal Erturk, MD
Jodi K. Maranchie, MD
Badar Munir Mian, MD, Chair
Nominating Committee
Gabriel P. Haas, MD
Barry Kogan, MD
William Hulbert, MD
Dawn MacLellan, MD
James W.L. Wilson, MD, Chair
10
Northeastern Section of the AUA — 2009 Annual Meeting
NORTH EASTERN S ECTION
RES EARCH AN D EDUCATION FU N D
The purpose of the NS-AUA Foundation is to operate exclusively for educational, scientific and charitable purposes, including, but not by way of limitation, to foster, support and conduct education (including education of the general public) and research in the field of urology.
The NS-AUA started funding research in 1995 through a grant from Searle Canada and Searle USA. A Research and Education Fund was established to assure the membership of the NS-AUA continuing excellence in research and educational activity within the Section. The NS-AUA Scholarship Program was established in 1998 to provide financial scholarships to
support research and educational projects. The Section offers up to two scholarship awards annually. These Young Investigator Awards provide financial assistance to a researcher in basic or clinical sciences related to urology, and to acquiring, developing or improving his or her knowledge and skills in a specific aspect of the specialty. In all, 19 researchers have been
awarded research scholarships.
Through the generosity of our Section members and corporate supporters, the Research and Education
Fund continues to grow. We gratefully acknowledge and thank:
Abbott
Cook (Canada) Inc.
Novartis Oncology
Abbott – Canada
Cook Urological Incorporated
Novartis Pharmaceuticals Corporation
Amgen Inc.
Endo Pharmaceuticals
NS-AUA Members
Astellas Pharma US Inc.
Flarsheim/Mallinckrodt
Olympus ACMI
AstraZeneca Canada Inc.
GlaxoSmithKline
Ortho-McNeil
AstraZeneca Pharmaceuticals LP
Healthtronics, Inc.
Pfizer Inc
Bayer Healthcare Pharmaceuticals
Janssen-Ortho Inc.
Pfizer Canada
Boehringer Ingelheim – Canada
Karl Storz Endoscopy – America, Inc.
Praecis Pharmaceuticals Incorporated
Boehringer Ingelheim Pharmaceuticals, Inc.
Karl Storz Endoscopy Canada Ltd.
Procter & Gamble Pharmaceuticals
Boston Scientific
Lilly USA, LLC
sanofi-aventis Group
Bristol-Myers Squibb
Merck US Human Health
Schering Oncology/Biotech
CR Bard
Merck Frosst Canada Ltd.
The Northeastern Section thanks the following companies for providing educational grants
in support of the 2009 Annual Meeting:
Allergan
Genentech BioOncology
Astellas Pharma US, Inc.
Ortho Women’s Health and Urology
Dendreon Corporation
Pfizer Inc
Endo Pharmaceuticals
sanofi-aventis U.S.
Ethicon Women’s Health and Urology
And the following companies for their general support of the Annual Meeting:
Abbott Oncology
Pfizer Inc
Astellas Pharma US, Inc.
Pfizer Canada, Inc.
AstraZeneca Canada Inc.
sanofi-aventis Canada, Inc.
Eli Lilly Canada, Inc.
VIVUS, Inc.
Ferring Pharmaceuticals
Watson Pharmaceuticals, Inc.
Olympus
11
PAST PRES I DENTS AN D M EETI NG VEN U ES
YEAR
1948-1949
1949-1950
1950-1951
1951-1952
1952-1953
1953-1954
1954-1955
1955-1956
1956-1957
1957-1958
1958-1959
1959-1960
1960-1961
1961-1962
1962-1963
1963-1964
1964-1965
1965-1966
1966-1967
1967-1968
1968-1969
1969-1970
1970-1971
1971-1972
1972-1973
1973-1974
1974-1975
1975-1976
1976-1977
1977-1978
1978-1979
1979-1980
1980-1981
1981-1982
1982-1983
1983-1984
1984-1985
1985-1986
1987-1988
1988-1989
1989-1989
1990-1991
1991-1992
1992-1993
1993-1994
1994-1995
1995-1996
1996-1997
1997-1998
1998-1999
1999-2000
2000-2001
2001-2002
2002-2003
2003-2004
2004-2005
2005-2006
2006-2007
2007-2008
*Deceased
PRESIDENT
James C. McClelland*
A. Lawrence Parlow*
William J. Kennedy*
William A. Barrett*
David R. Mitchell*
Albert M. Crance*
Walter J. Hayward*
William Baurys*
Allan B. Hawthorne*
William A. Milner*
S. H. Johnson III*
Frances O. Harbach*
J. Victor Berry*
John S. Fitzgerald*
Hollister W. Lyon*
John A. Benjamin*
Arthur Bedard*
Michael G. O'Brien*
William B. Garlick*
William E. Collins*
David W. Kline*
Hobart L. Boyd*
Charles L. Robson*
Charles C. Altman*
William J. Staubitz*
Lloyd N. McAninch*
Stuart E. Price*
Peter O. Crassweller
Otto M. Lilien*
John F. Rose Jr.
Andrew W. Bruce
Abraham A.T. Cockett
Alan H. Irvine*
Andre Vallieres
Leo M. King
Irwin N. Frank
Martin Barkin
Pierre E. Bertrand
David H. Barnhouse
Grant A. Farrow
Jack L. Sales
Marcus L. Shoobe
Said A. Awad
Alan H. Bennett
Normand Sullivan*
Anthony V. Passaretti*
Mostafa M. Elhilali
Ronald Rabinowitz
David B. Patrick
Alvaro Morales
Kevin Pranikoff
R. Brewer Auld
Datta G. Wagle
Joseph L. Chin
Mark F. Bellinger
John D. Denstedt
Gabriel P. Haas
Barry A. Kogan
James W. L. Wilson
PRESIDENT’S HOME
Toronto, ON
Rochester, NY
Gloversville, NY
Pittsburgh, PA
Toronto, ON
Geneva, NY
Jamestown, NY
Sayre, PA
Montreal, QC
Albany, NY
Pittsburgh, PA
Syracuse, NY
Ottawa, ON
Utica, NY
Punxsutawney, PA
Rochester, NY
Quebec City, QC
Scranton, PA
Albany, NY
Ottawa, ON
Greenville, PA
Rochester, NY
Toronto, ON
Pittsburgh, PA
Buffalo, NY
London, ON
Pittsburgh, PA
Toronto, ON
Syracuse, NY
Danville, PA
Kingston, ON
Rochester, NY
Ottawa, ON
Quebec City, QC
McKeesport, PA
Rochester, NY
Toronto, ON
Quebec City, QC
Pittsburgh, PA
Toronto, ON
London, ON
Albany, NY
Halifax, NS
Albany, NY
St. Anne de Sorel, QC
Albany, NY
Montreal, QC
Rochester, NY
Beaver, PA
Kingston, ON
Buffalo, NY
Halifax, NS
Williamsville, NY
London, ON
Pittsburgh, PA
London, ON
Syracuse, NY
Albany, NY
Kingston, ON
ANNUAL MEETING VENUE
Bigwin Inn, Huntsville, ON
The Sagamore, Lake George, NY
Lake Placid Club, Lake Placid, NY
Hamilton Princess, Bermuda
Shawnee Inn, Shawnee on Delaware, PA
Chateau Frontenac, Quebec City, QC
Lake Placid Club, Lake Placid, NY
Equinox House, Manchester, VT
Whiteface Inn, Lake Placid, NY
Equinox House, Manchester, VT
Seignory Club, Montebello, QC
Bedford Springs Resort, Harrisburg, PA
Equinox House, Manchester, VT
Grossinger's, Liberty, NY
Chateau Frontenac, Quebec City, QC
Pocono Manor, Pocono Manor, PA
Otesaga Hotel, Cooperstown, NY
Shawnee Inn, Shawnee on Delaware, PA
The Sagamore, Lake George, NY
Whiteface Inn, Lake Placid, NY
Whiteface Inn, Lake Placid, NY
Hershey Hotel, Hershey, PA
King's Inn, Freeport, Grand Bahamas
Sheraton Hyannis, Cape Cod, MA
Inn on the Park, Toronto, ON
Mountain View House, Whitefield, NH
Buck Hill Inn, Buck Hill Falls, PA
The Homestead, Hot Springs, VA
Chateau Frontenac, Quebec City, QC
Lake Placid Club, Lake Placid, NY
Hotel Bonaventure, Montreal, QC
Copley Plaza Westin Hotel, Boston, MA
Chateau Laurier Hotel, Ottawa, ON
The Nevele Country Club, Ellenburg, NY
Chateau Frontenac, Quebec City, QC
Albany Hilton, Albany, NY
The Copley Plaza Westin Hotel, Boston, MA
The Four Seasons Hotel, Toronto, ON
The Breakers, Palm Beach, FL
Hamilton Princess, Bermuda
Chateau Champlain, Montreal, QC
Halifax Sheraton, Halifax, NS
Colonial Williamsburg, VA
Toronto Hilton, Toronto, ON
El San Juan Hotel, San Juan, PR
The Sagamore, Lake George, NY
Cairo Marriott Hotel, Cairo, Egypt
Buffalo Hilton, Buffalo, NY
Wigwam Resort, Phoenix, AZ
Royal York Hotel, Toronto, ON
The Westin Hotel, Pittsburgh, PA
Boca Raton Resort, Boca Raton, FL
Fairmont Mt. Tremblant, Mount Tremblant, QC
Halifax World Trade Centre, Halifax, NS
Westin Hotel, Savannah, GA
Southampton Princess, Bermuda
Westin Hotel, Ottawa, ON
Hyatt Regency, Rochester, NY
Hyatt Tamaya, Santa Ana Pueblo, NM
12
Northeastern Section of the AUA — 2009 Annual Meeting
DR. G EORG E E. S LOTKI N
Excerpt from the Waterways chapter: “No history of the
Northeastern Section is complete without a short biography of this indefatigable urologist.
His later work with E.A. Mercer, ‘Case of epispadias with a
double urethra,’ was published in The Journal of Urology in
1953.
Dr. George E. Slotkin (1890-1971) was born in New York
City but soon moved with his parents to Buffalo, NY, where
he spent his professional career. We acknowledge him
today as a founder, the first benefactor, and the first historian of the NS, but there is more to his story.
Obviously, this change in his work reflects the change in
urology from its early focus on genitourinary disease to its
present focus as a surgical specialty. Dr. Slotkin was named
Clinical Professor of Urology Emeritus in 1954 by the University of Buffalo Medical School and continued his private
practice until 1964. After retirement, he continued to write,
contributing a fascinating chapter about the history of the
Northeastern Section to History of Urology. It is a priceless,
logical record of carefully researched facts.
If one were to hold up a mirror to the changing face of
urology in the first half of the 20th century, it would be well
reflected with an image of George E. Slotkin. A graduate of
the University of Buffalo Medical School, Dr. Slotkin did
postgraduate work at the New York City Post Graduate
Hospital, the University of Vienna, and the University of Budapest. In 1918, he became a clinical professor of urology
at the University of Buffalo. During the late 1940s, his clinical interest was tuberculosis of the urinary tract, which he
treated with chalamagoric acid. Even though results of his
work in this area remain inconclusive, other fruits of his career do not. Friends and colleagues of his time were fond
of saying, ‘George Slotkin has three loves: urology, his wife
Helene, and his Rolls Royce...not necessarily in that order!’
His early work, ‘Nephroptosis, a resurrected disease,’ was
published in The Urologic and Cutaneous Review in 1938.
His obituary notice implies that he may have been the first
American invited to join the Canadian Urological Association. Dr. and Mrs. Slotkin did not have any children; his estate included a generous bequest to the Northeastern
Section to provide funding for invited guest speakers at our
annual meetings.”
Meyer, Robert, MD and Margaret, “History of the Northeastern Section
of the American Urological Association: Waterways.” The American
Urological Association Centennial History 1902 – 2002. Ed. Lawrence
Jones, MD and Paul Peters, MD Baltimore: The American Urological
Association, 2001. 585-642.
G EORG E E. S LOTKI N LECTU RERS
1975 Prof. Willie L. M. Gregoir, Brussels, Belgium
1994 Carl Olsson, MD, Larchmont, New York
1976 J. Engelbert Dunphy, MD, San Francisco, California
1995 Peter Scardino, MD, Houston, Texas
1977 B. E. Christopher Nordin, MD, Leeds, England
1996 Bernard M. Churchill, MD, Los Angeles, California
1978 Donald Smith, MD, Piscataway, New Jersey
1997 Peter R. Carroll, MD, San Francisco, California
1979 J. Genest, MD, Montreal, Quebec
1998 Joyce Lisa Tenover, MD, Atlanta, Georgia
1980 Joseph J. Kaufman, MD, Los Angeles, California
1999 Richard D. Williams, MD, Iowa City, Iowa
1981 Roger C. B. Pugh, MD, London, England
2000 Gerry G. Blaivas, MD, New York, New York
1982 Donald S. Coffey, MD, Baltimore, Maryland
2001 Alvaro Morales, MD, Kingston, Ontario
1983 Martin I. Resnick, MD, Cleveland, Ohio
2002 Edson Pontes, MD, Detroit, Michigan
1984 Willet F Whitmore Jr., MD, New York, New York
2003 Gerald L. Andriole, MD, St. Louis, Missouri
1985 Peter Scardino, MD, Houston, Texas
2004 Mustafa Elhilali, MD, Montreal, Quebec
1986 William Fair, MD, New York, New York
2005 Margaret Sue Pearle, MD, Dallas, Texas
1987 John Duckett, MD, Philadelphia, Pennsylvania
2006 Mani Menon, MD, Detroit, Michigan
1988 Anthony R. Mundy, MD, London, England
2007 Darius Jehan Bagli, MD, Toronto, Ontario
1989 Robert Jeffs, MD, Baltimore, Maryland
2008 S. Larry Goldenberg, MD, Vancouver, British Columbia
1990 Charles J. Devine, MD, Norfolk, Virginia
2009 Sir Philip G. Ransley, MD, London, United Kingdom
1991 Thomas Stamey, MD, Stanford, California
1992 Michael E. Mitchell, MD, Seattle, Washington
1993 Donald S. Coffey, MD, Baltimore, Maryland
13
2009 Invited Guest Speakers
Gerald B. Brock, MD
hances the learning of clinical aspects of surgical training.
Professor, Department of Surgery
For the years to come, Dr. Jolivet will be active coordinating
clerkship common efforts to provide the highest quality standards of excellence in health services, to be eligible for the habilitation standards supported by the accreditation process for
public health in North America.
St. Joseph’s Health Centre
London, ON, Canada
Gerald Brock, MD, is Professor, Department of Surgery,
Division of Urology, at St. Joseph’s Health Centre in London,
Ontario. He completed his Medical and Urology Degrees at
McGill University in Montreal and subsequently did a two year
fellowship in neurourology at the University of California, San
Francisco. He currently runs a large tertiary care erectile dysfunction clinic at St. Joseph’s Health Care, where he sees between 2,000 to 2,500 new consults annually. In addition to his
responsibilities as resident program director, he runs a productive basic animal research lab evaluating the impact of disease
on erectile mechanisms.
Dr. Brock is an active participant in professional associations,
previous chair of the Canadian Male Sexual Health Council (affiliate of the Canadian Urology Association - CUA), past chair of
the Guidelines Committee of the CUA. He currently serves as
the administrative chair of the CUA Scholarship Fund, treasurer
of the Canadian Urology Research Consortium and serves as
chair of the Scientific Research Committee of the Canadian Society for the Study of the Aging Male.
Dr. Brock is the author of over 130 peer reviewed publications,
25 book chapters as well as numerous abstracts. Over the past
decade he has been invited to speak across Canada, the United
States, Europe, Australia and Asia. Dr. Brock has been awarded
over 20 research prizes for his clinical and basic research endeavours evaluating the impact of disease states on erectile and
ejaculatory mechanisms.
Dr. Brock’s work in urology and erectile dysfunction is acknowledged by his role as Editor-in-Chief of Chronicles of Urology
and Sexual Health, CME Section Editor of the Journal of Sexual
Medicine, Andrology Section Editor of the CUA Journal.
Martine Jolivet-Tremblay, MD
Eric A. Klein, MD
Chairman, Glickman Urological and Kidney Institute
Professor of Surgery,
Cleveland Clinic Lerner College of Medicine
Cleveland, OH
Eric A. Klein, MD is professor of surgery in the Lerner College
of Medicine and interim chair of the Glickman Urological and
Kidney Institute of the Cleveland Clinic. Following undergraduate training at Johns Hopkins University, he was a cum laude
graduate of the University of Pittsburgh School of Medicine. He
subsequently completed residency training in urology at the
Cleveland Clinic and a fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center. He joined the staff of the
Cleveland Clinic in 1989 and currently serves as chair of the
Glickman Urological and Kidney Institute.
Dr. Klein’s clinical and research interests cover all of urologic
oncology and particularly clinical trials for localized and locally
advanced prostate cancer. He serves as the chair of the Localized Prostate Cancer Committee of the Southwest Oncology
Group and is the National Study Coordinator for the NCI-sponsored Selenium and Vitamin E Cancer Prevention Trial (SELECT). Dr. Klein has contributed more than 300 papers to the
scientific literature, authored or edited seven books on urologic
malignancies, and serves as the Editor-in-Chief of Urology. He
has delivered more than 200 invited scientific lectures including
eight named lectureships, and has served as a Visiting Professor
at more than 45 institutions around the world. Dr. Klein is a codiscoverer of XMRV, a novel human virus found in men genetically predisposed to prostate cancer.
Professor, Department of Surgery
University of Montreal
John M. Fitzpatrick, MD
Montreal, QC, Canada
Professor
Mater Misericordiae Hospital
14
Dr. Jolivet has been a urologist for ten years and works at the
I’Hôpital Saint-Luc du CHUM, as well as an assistant professor
in surgery department at the Université de Montréal. Within the
last few years, Dr. Jolivet has also worked as the clerkship director for the MD program. Her postgraduate training was in
neuro-urology in Toronto. Moreover, she is the recipient of the
2007's Wilbrod-Bonin Prize from the University of Montreal.
Convinced of the importance of clinical education in medicine,
Dr. Jolivet believes in a new approach in education that en-
Dublin, Ireland
John Fitzpatrick, MD, was born and educated in Dublin. He
qualified as a doctor in 1971 and become fellow of the Royal
College of Surgeons in Ireland in 1975. He received his Masters
degree in 1976. He is also a fellow of the Royal College of Surgeons of England and of Glasgow.
Between 1977 and 1981, Professor Fitzpatrick trained in the St.
Northeastern Section of the AUA — 2009 Annual Meeting
Peters Hospitals and the Institute of Urology in London. In 1981,
Professor Fitzpatrick returned to Dublin as Consultant Urologist
and Senior Lecturer in Urology in the Meath and St. James'
Hospitals and Trinity College Dublin. In 1986, Professor Fitzpatrick was appointed Professor and Chairman of the Department of Surgery in the Mater Misericordiae Hospital and
University College Dublin.
Professor Fitzpatrick has performed 45 visiting professorships in
the United States and other countries throughout the world. He
has also given 167 guest lectures throughout the world. He has
produced 260 peer reviewed publications, 74 book chapters,
has edited six journal editions, and published 12 books.
Professor Fitzpatrick is on the editorial board of 25 journals, and is
editor-in-chief of the BJU International. He is president of the Irish
Society Urology and is immediate past president of the British Association of Urological Surgeons. He is a member of the Board of
Trustees of the British Urological Foundation and is chair of the
Scientific Committee of that Foundation. He is an honorary fellow
of the College of Urologists of South Africa and an honorary
member of the British Association of Urological Surgeons and of
the American Urological Association as well as an Honorary
member of the Urological Societies of Australasia, South Africa,
Germany, Netherlands, Hungary, Argentina, Greece, and Georgia.
Edward M. Messing, MD
W.W. Scott Professor
Chairman, Dept. of Urology
Professor of Oncology and Pathology
University of Rochester School of Medicine and Dentistry
Rochester, NY
Dr. Messing received his MD degree from New York University
in 1972, completed his surgery training at NYU-Bellevue
Hospital in New York 1972-1974 and his Urology Residency at
Stanford University 1974-1978. After two years on the faculty at
Tulane University, he completed a fellowship in urologic oncology at UCLA in 1982. He was on the faculty of the Division of
Urology at the University of Wisconsin from 1982-1995, being
director of their Urologic Oncology Program for the last 10
years. He assumed his current position at the University of
Rochester School of Medicine and Dentistry in September
1995. Dr. Messing is a renowned expert in the diagnosis and
treatment of cancers of the bladder, prostate, kidney and other
genitourinary organs. He carries on extensive research in the
basic biology of bladder and prostate cancers, and has been
the principal investigator on numerous clinical studies for the
detection, prevention and treatment of genitourinary cancers.
Among other activities, he has designed, conducted and reported on two large randomized phase III trials germane to his
presentations at the NS-AUA Meeting: The use of adjuvant interferon alpha for completely resected local/regionally extensive
renal cell cancer (J Clin Oncol 21:1214-1222, 2003); the use of
adjuvant ADT for N+ prostate cancer following radical prostatectomy (EST 3886; NEJM 341:24;1781-1788, 1999; Lancet
Oncology, 7(6):472-9;2006).
Robert M. Moldwin, MD, FACS
Associate Professor, The Smith Institute for Urology
Long Island Jewish Medical Center
Long Island, NY
Robert M. Moldwin, MD is associate professor of Clinical Urology at Hofstra University School of Medicine and director of the
Pelvic Pain Center at The Smith Institute for Urology of the
North-Shore–Long Island Jewish Healthcare System. Dr. Moldwin’s career spans 18 years during which time he has functioned as a clinician, researcher, patient advocate and media
consultant, primarily focusing upon topics related to urologic infectious/ inflammatory disease and pelvic pain syndromes. He
travels extensively as a national and international lecturer. Media
hits include: CNN, You Tube, CBS News, Cosmopolitan,
Woman’s Day, Newsday, Oxygen, Men’s Health, Self Magazine
and Ladies Home Journal, among others.
Dr. Moldwin’s primary research interests rest with urological
pain syndromes such as Interstitial cystitis/painful bladder
syndrome (IC/PBS) and chronic prostatitis/chronic pelvic pain
syndrome (CP/CPPS), conditions that are considered present in
over four million people in the United States.
He has published extensively in peer-reviewed journals. ”The Interstitial Cystitis Survival Guide,” by Dr. Moldwin, was the first
physician-written book exclusively related to interstitial cystitis for
healthcare professionals and patients. Dr. Moldwin’s research has
been published in Cancer, Contemporary Urology, Current Urology Reports, Women’s Healthcare, The Canadian Journal of Urology, The British Medical Journal, The Journal of Urology® and
Urology. He is a reviewer for medical journals including The Journal of Urology®, Urology, The Journal of Endourology, The Medical Letter, and The Journal of Pelvic Surgery.
Dr. Moldwin earned his undergraduate degree at Adelphi University in Garden City, NY, and his medical degree at the University of Chicago, Pritzker School of Medicine in Chicago, IL. He
completed residencies in general surgery and urology at the
Long Island Jewish Medical Center. He also served as a Valentine fellow, studying infectious and inflammatory urological diseases in the Department of Urology at Thomas Jefferson
Medical College in Philadelphia, PA
Dr. Moldwin currently serves on multiple medical advisory
boards including the Interstitial Cystitis Association. He is a
member of The American Urological Association, The American
Association of Clinical Urologists, The International Association
for the Study of Pain, and The Society for Urodynamics and Female Urology. This year, Dr. Moldwin begins his tenure as President of the Society for Infection and Inflammation in Urology.
15
Francesco Montorsi, MD
Professor of Urology, Department of Urology
University Vita-Salute San Raffaele
Milan, Italy
Francesco Montorsi, MD, is professor of urology at University VitaSalute San Raffaele, Department of Urology, in Milan, Italy. He is
also Head of the Sexual Medicine Center and an attending urologist, Department of Urology, at San Raffaele Hospital in Milan.
Prof. Montorsi received his medical degree from the University
of Milan School of Medicine, where he also completed a residency in urology. In addition, he completed a residency in andrology at the University of Pisa School of Medicine.
Prof. Montorsi’s major research interests have included several
urological areas with a specific focus on pathophysiology, diagnosis and management of sexual dysfunctions, prostate cancer
and benign prostatic hyperplasia.
As a widely published author, Prof. Montorsi has co-authored
more than 400 peer reviewed journal articles and several book
chapters. His most recent contributions to the literature have
been on the management, treatment, and pathophysiology of
male and female sexual dysfunctions, prostate cancer and benign prostatic hyperplasia. His articles have been published in
many prestigious journals including The Lancet, Journal of Clinical Oncology, European Heart Journal, Diabetes Care, European
Urology, International Journal of Cancer, European Journal of
Cancer, Journal of Sexual Medicine, Drugs, Journal of Urology®,
British Journal of Urology International, Urology, The International Journal of Impotence Research, Surgery, Hormones and
Behavior and Current Opinion of Urology.
He is editor-in-chief for European Urology (IF: 6.512) and for
European Urology Supplements (IF: 1.711). He is a reviewer for
The Lancet, JAMA, European Urology, The Journal of Urology®,
Urology, Urological Research, British Journal of Urology
International, International Journal of Impotence Research,
World Journal of Urology and The Journal of Sexual Medicine.
Prof. Montorsi holds positions in several international professional organizations including past-president of the European
Society for Sexual Medicine. Prof. Montorsi has been designated as chair of the 2009 International Consultation on Sexual
Dysfunctions sponsored by the WHO.
J. Curtis Nickel MD, FRCSC
Professor, Department of Urology, Queen’s University,
CIHR Tier 1 Canada Research Chair in
Urologic Pain and Inflammation
Staff Urologist, Department of Urology, Kingston General Hospital
16
Kingston, Ontario, Canada
ber of the Department of Urology at Queen’s University since
1984 (promoted to Professor in 1994). Dr. Nickel’s research has
been in the fields of inflammatory diseases of the urinary tract
and benign diseases of the prostate gland. He has written over
400 scientific papers, reviews, chapters and books on these
subjects. He has given invited lectures in over forty countries.
His work in prostatitis, interstitial cystitis and BPH has led to
new appreciation of these conditions, provided epidemiological
support for their importance, updated definitions and classifications, validated outcome parameters and his multiple clinical
treatment trials have provided an evidence based foundation for
therapy. He has served on the examination committee and as an
examiner for the American Board of Urology and is presently on
the examination committee of the Royal College of Physicians
and Surgeons of Canada. He has been a member of the American Association of Genito-urinary Surgeons since 2004. He was
recently appointed as the CIHR Canada Research Chair in Urologic Pain and Inflammation.
Sir Philip G. Ransley, M.A., M.B., B.Chir.,
FRCS, FRCS (Ed., Hon.), FAAP (Hon.).
Consultant, Pediatric Urologist
London, England
Mr. Ransley graduated from the University of Cambridge with
clinical training at Guy’s Hospital and proceeded to Fellowship
of the Royal College of Surgeons of England in 1971. He trained
in general surgery and urology before specialising in pediatric
urology. He was trained by Sir David Innes Williams and appointed to the staff of Great Ormond Street Children’s Hospital
in 1977, where he worked until his retirement in 2004. He held
additional appointments at the St Peters’ Hospitals (Institute of
Urology) and latterly at Guy’s Hospital. He held an academic
appointment with University College London as senior lecturer
in pediatric urology at the Institute of Child Health.
He served on the Board of the European Society for Paediatric
Urology and as it’s President from 1996-2000. He has been
made an honorary fellow of the American Academy of Pediatrics and recently received an honorary fellowship from the
Royal College of Surgeons of Edinburgh.
Since his retirement Mr. Ransley has been active in several institutions around the world, but in particular at the Sindh Institute
of Urology and Transplantation in Karachi, Pakistan, where he
has established a thriving pediatric urology unit, providing free
treatment for a wide variety of complex pediatric urological
disorders from all over Pakistan.
He has a lifetime’s interest in astronomy and for the last 20
years has been chasing total solar eclipses around the globe.
He currently observes the night sky from the mountains around
his home at Lake Como in Italy.
J. Curtis Nickel, MD, completed his undergraduate, surgical, urological and research training in Canada. He has been a mem-
Northeastern Section of the AUA — 2009 Annual Meeting
Breakaway
Shahrokh F. Shariat, MD
Fellow, Division of Urology
Memorial Sloan Kettering Cancer Center
and take a shot on winning a $150 Visa gift card!
New York, NY
Shahrokh F. Shariat is a fellow at the Division of Urology at
Memorial Sloan Kettering Cancer Center, New York, NY. He is a
member of various academic societies, national committees,
and editorial boards. His published scientific papers focus on
translational research in urologic oncology, molecular mechanisms, markers, early detection, natural history, treatment, translational and outcomes research as well as gene and vaccine
therapies. He has published over 250 articles in both national
and international journals and a dozen book chapters. He is
currently spearheading several collaborative groups and
prospective clinical trials; he has had continuous NIH funding.
Visit the NS-AUA hockey game on
the Exhibit Floor during Exhibit Hall hours.
Publication of Abstracts – 2009
The Board of Directors of the NS-AUA is pleased to announce that all accepted abstracts of the 2009 annual meeting
have been published in a supplement to the October issue of the Canadian Urological Association Journal (CUAJ). A
copy of this issue and supplement of CUAJ will be distributed with this program book.
On behalf of the authors, the Executive Officers extend its sincerest thanks and appreciation to the Canadian Urological
Association Journal (CUAJ). CUAJ is owned and officially endorsed by the Canadian Urological Association. CUAJ is a bimonthly publication and is searchable on PubMed, with full-text articles on PubMed Central and on the newly created
CUAJ website (www.cuaj.ca). CUAJ is also covered in the Science Citation Index Expanded (also known as SciSearch)
and the Journal Citation Reports/Science Edition provided by Thomson Reuters. Journal editors welcome your
manuscripts for review and consideration for publication.
For additional information on submitting manuscripts or subscription information, contact:
Josephine Sciortino
Managing Editor, CUAJ
1155 University, Suite 1303
Montréal, QC, Canada H3B 3A7
Phone: +1 514 395-0376, ext. 40
Fax: +1 514 395-1664
E-mail: [email protected]
Web site: www.cuaj.ca
17
Scientific Program
*Subject to Change
Paul Perrotte1, Pierre I. Karakiewicz1
THURSDAY, OCTOBER 8, 2009
7:30 a.m.
Opening Session
Anne-Marie Houle
Northeastern Section President
University of Montréal, Montréal, QC, Canada;
Vita-Salute San Raffaele, Milan, Italy
1
2
11:12 a.m.
Anton J. Bueschen
American Urological Association President
7:45 – 9:45 a.m.
7:45 a.m.
7:50 a.m.
Plenary I
Lars Budäus1, Hendrik Isbarn2, Felix F. K. Chun3,
Caludio Jeldres1, Sascha A. Ahyai3, Thomas
Steuber2, Roman Heuer3, Mario Zacharias3,
Thorsten Schlomm2, Georg Salomon2, Alexander
Haese2, Hans Heinzer2, Hartwig Huland2, Markus
Graefen2, Pierre I. Karakiewicz1
Welcome and Introduction
Erectile Dysfunction (ED) after Radical
Prostatectomy
Francesco Montorsi,
Università Vita Salute, Milan, Italy
Gerald Brock, London, ON, Canada
University of Montréal, Montréal, QC, Canada;
Martiniclinic, Prostate Cancer Center HamburgEppendorf, Hamburg, Germany; 3University Hospital
Hamburg-Eppendorf, Hamburg, Germany
1
Panel: Francois Benard and Serge Carrier
Moderator: Paul Perrotte
8:40 a.m.
2
Locally Advanced and Metastatic RCC
John Fitzpatrick
11:15 a.m.
Panel: Paul Perrotte, Francois Patenaude,
and Simon Tanguay
Moderator: Pierre Karakiewicz
11 a.m.
Break
Concurrent Poster Sessions
View Posters
Welcome and Introduction
Moderated Poster Session I:
Prostate Cancer
Moderators: Francesco Montorsi and
Alexandre R. Zlotta
P1. Pelvic Radiation in Patients with a
Ross Bauer, William Conners, Badar Mian
Stratton VA Medical Center, Albany, NY, United States.
11:18 a.m.
University of Pittsburgh Medical Center,
Pittsburgh, PA, United States
11:21 a.m.
P2. Management of Prostate Cancer
Sunnybrook HSC, Toronto, ON, Canada
11:24 a.m.
Following Solid Organ Transplantation
1Roswell Park Cancer Institute, Buffalo, NY, United
States; 2National Cancer Institute, Bethesda, MD,
United States
University of Pittsburgh School of Medicine,
Pittsburgh, PA, United States
P3. A Systematic Analysis of the
Detrimental Effect of Orchiectomy on
12 Systemic Morbidities
11:27 a.m.
Valerie Deslauriers1, Hendrik Isbarn1, Claudio
Jeldres1, Giovanni Lughezzani1, Maxine Sun1,
Philippe Arjane1, Hugues Widmer1, Daniel
Pharand1, Francesco Montorsi2, Paul Perrotte1,
Pierre I. Karakiewicz1
University of Montréal, Montréal, QC, Canada;
Vita-Salute University, Milan, Italy
2
18
P4. A Systematic Analysis of the
Detrimental Effect of Orchiectomy
on Four Skeletal Morbidities
Claudio Jeldres1, Umberto Capitanio1, Hendrik
Isbarn1, Giovanni Lughezzani1, Shahrokh F.
Shariat1, Maxine Sun1, Daniel Pharand1, Hugues
Widmer1, Philippe Arjane1, Francesco Montorsi2,
P10. High-Grade Prostatic Intraepithelial
Neoplasia (HG-PIN) on Initial Prostate
Biopsy Is Not a Risk Factor for Prostate
Cancer at Repeat Biopsy
Lars Budäus1, Christopher R. Porter2, Claudio
Jeldres1, Kora Tang3, Sascha A. Ahyai4, Felix K. H.
Chun4, Hendrik Isbarn3, Georg Salomon3,
Thorsten Schlomm3, Alexander Haese3, Thomas
Steuber3, Hans Heinzer3, Hartwig Huland3,
Markus Graefen3, Pierre I. Karakiewicz1.
1
11:09 a.m.
P9. Racial Differences in Risk
Perception and Receipt of PSA Testing
Willie Underwood III1, Vickie L. Shavers2,
Richard P. Moser2
Jeff Larson, Jeffrey J. Tomaszewski, Marc C.
Smaldone, Stephen V. Jackman
11:06 a.m.
P8. Clinical Results of Long-Term
Follow-up of a Large Active
Surveillance Cohort
Laurence Klotz, Adam Lam, Alex Mladenov,
Gerard Morton, Andrew Loblaw
David M. Berlach, Marylene Brodeur, DABR,
Fabio Cury
11:03 a.m.
P7. The Impact of Surgeon Fatigue on
Performance of Open Radical Retropubic Prostatectomy
Marc C. Smaldone, Jeffrey J. Tomaszewski,
Joel B. Nelson
Pelvic Kidney: No Longer Playing with
Fire
McGill University, Montréal, QC, Canada
P6. National Patterns of Diagnosis and
Treatment of Localized Prostate Cancer at
Veterans Administration Medical Centers
Mater Misericordial Hospital, Dublin, Ireland
9:45 – 10:15 a.m.
10:15 a.m. - Noon
10:15 – 10:45 a.m.
10:45 – 11 a.m.
11 a.m. – Noon
P5. External Validation of a
Postoperative Nomogram Predicting
the Probability of Prostate Cancer
Recurrence After Radical Prostatectomy
1University of Montréal, Montréal, QC, Canada; 2Virginia Mason Medical Center, Seattle, WA, United
States; 3Martiniclinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany; 4University Hospital Hamburg-Eppendorf, Hamburg, Germany
11:30 a.m.
P11. Unilateral Prostate Cancer Cannot
Be Reliably and Accurately Diagnosed
Northeastern Section of the AUA — 2009 Annual Meeting
Prize-winning Essays
LOOK FOR THIS ICON
with Systematic 10 or More Core Biopsy
1
2
Maxine Sun1, Francesco Montorsi3, Paul
Perrotte1, Pierre I. Karakiewicz1
1
Lars Budäus , Hendrik Isbarn , Claudio Jeldres ,
Sascha A. Ahyai3, Thorsten Schlomm2, Georg
Salomon2, Hans Heinzer2, Thomas Steuber2,
Alexander Haese2, Hartwig Huland2, Markus
Graefen2, Felix K. H. Chun3, Pierre I. Karakiewicz1
1University of Montréal, Montréal, QC, Canada; 2Martiniclinic, Prostate Cancer Center Hamburg-Eppendorf,
Hamburg, Germany; 3University Hospital HamburgEppendorf, Hamburg, Germany
11:33 a.m.
1University of Montréal, Montréal, QC, Canada; 2Lille
University Hospital, Lille, France; 3Vita Salute University
San Raffaele, Milan, Italy; 4Martiniclinic, Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany
11:48 a.m.
Jonah S. Marshall, Allison L. Cardin, Eric A.
Singer, Andrew Tompkins, Edwin van
Wijngaarden, Paul Winters, Ralph Brassachio,
Dragan Golijanin, Edward M. Messing
P12. Presence of Prostate Cancer at
Saturation Biopsy Can Be Accurately
Predicted
Lars Budäus1, Sascha A. Ahyai2, Hendrik Isbarn3,
Felix K. H. Chun2, Matthias Reichert2, Thomas
Steuber3, Hans Heinzer3, Georg Salomon3, Paul
Perrotte1, Hartwig Huland3, Markus Graefen3,
Alexander Haese3, Pierre I. Karakiewicz1
1University of Montréal, Montréal, QC, Canada; 2University Hospital Hamburg-Eppendorf, Hamburg, Germany; 3Martiniclinic, Prostate Cancer Center
Hamburg-Eppendorf, Hamburg, Germany
11:36 a.m.
University of Rochester, Rochester, NY, United States
11:51 a.m.
Noon
11 a.m. – Noon
11 a.m.
P13. Are All Low-Risk Prostate Cancer
Clay W. Mechlin1, Matt Tanner2, Badar Mian3,
Ralph Buttyan2.
Albany Medical Center, Albany, NY, United States;
Ordway Research Center, Albany, NY, United States;
3Albany Medical Center, Stratton VA Medical Center,
Albany, NY, United States
1
2
11:03 a.m.
University of Montréal, Montréal, QC, Canada; 2Martiniclinic, Prostate Cancer Center Hamburg-Eppendorf,
Hamburg, Germany; 3University Hospital Hamburg-Eppendorf, Hamburg, Germany
1
11:39 a.m.
P14. Does Maximal Percent of Core
Biopsy Positive for Prostate Cancer
Correlate to Predictors of Disease
Recurrence?
University of Pittsburgh, Pittsburgh, PA, United States;
William Beaumont, Royal Oak, MI, United States
1
2
11:06 a.m.
P15. Comparison of Tertiary Center and
Referred Prostate Biopsies: Impact of
Re-Review on Gleason Score Accuracy
University of Pittsburgh, Pittsburgh, PA, United States
11:09 a.m.
Joice Rocha, Amina Zoubeidi, Fatima Zouanat,
Lucie Hamel, PhD, Eleonora Scarlata, Armen
Aprikian, Simone Chevalier
Albany Medical College, Albany, NY, United States;
Stratton VA Medical Center, Albany, NY, United
States
1
2
McGill, Montréal, QC, Canada
P16. Systematic Assessment of Total
11:12 a.m.
Prostate Specific Antigen (PSA) and
Percentage Free/Total PSA on the
Rate of Biopsy Recommendation: A
Population-Based Study
2
P21. Prostate Cancer Progression
Through the Fer Kinase, a Potent
Regulator of Androgen Receptor
Signaling
Michael A. Feuerstein1, Michael Hong1, Tipu
Nazeer2, Hugh Fisher1, Ronald Kaufman, Jr.1,
Badar M. Mian2
1
P20. Cannabinoid Receptors in Human
Urothelial Carcinoma
Ruthie Su, Vikas Tyagi, Brian Phillips, Pradeep
Tyagi, Naoki Yoshimura
University of Rochester, Rochester, NY, United States
11:45 a.m.
P19. Effect of Neoplasia in the Urinary
Tract on Urine Levels of CC Chemokines:
A Cross-Sectional Study
Bruce L. Jacobs1, Yoram Vodovotz1, Vikas Tyagi1,
Derek Barclay1, Stephen V. Jackman1, Wendy W.
Leng1, Pradeep Tyagi2
Matthew M. Lux, Tricia D. Greene, Erdal Erturk,
Jean V. Joseph
11:42 a.m.
Discussion
Adjourn
Moderated Poster Session II:
Basic Research
Moderators: Shahrokh Shariat and
Jean-Baptiste Lattouf
P18. Evaluation of Hedgehog Signaling
in Human Transitional Carcinoma Cell
Lines
Patients Created Equally?
Lars Budäus1, Hendrik Isbarn2, Sascha A. Ahyai3,
Felix K. H. Chun3, Claudio Jeldres1, Alexander
Haese2, Hans Heinzer2, Mario Zacharias3, Roman
Heuer3, Thomas Steuber2, Georg Salomon2,
Thorsten Schlomm2, Paul Perrotte1, Margit Fisch3,
Hartwig Huland2, Markus Graefen2, Pierre I.
Karakiewicz1
P17. Initial Experience with Prostate
Brachytherapy: Ten-Year Results from a
Single Surgeon at a Single Institution
3
Al'a Abdo , Laurent Zini , Umberto Capitanio ,
Hendrik Isbarn4, Claudio Jeldres1, Shahrokh F.
Shariat1, Georg Hutterer1, Giovanni Lughezzani1,
P22. Effect of Combined EGFR Inhibition
and PPAR Gamma-Agonist in Bladder
Cancer Therapy
Jose J. Mansure, Konrad Szymanski, Roland
Nassim, Joice Rocha, Saad AldoUnited Statesri,
Saad AldoUnited Statesri, Simone Chevalier,
Wassim Kassouf.
McGill University Health Center, Montréal, QC, Canada
19
11:15 a.m.
P23. The FGFR3 Mutation Is Related to
Favorable pT1 Bladder Cancer
Bas W. G. van Rhijn1, Bharati Bapat2, Theo H. van
der Kwast1, Liyang Liu3, Neil E. Fleshner1,
Madelon N. M. van der Aa4, Rati Vajpeyi5, Chris
H. Bangma4, Ellen C. Zwarthoff6, Michael A. S.
Jewett1, Alexandre R. Zlotta7
University of Toronto, University Health Network,
Toronto, ON, Canada; 2University of Toronto and Mount
Sinai Hospital, Toronto, ON, Canada; 3Mount Sinai Hospital, Toronto, ON, Canada, 4Josephine Nefkens Institute, Erasmus MC, Rotterdam, Netherlands; 5University
Health Network, Toronto, ON, Canada; 6Josephine Nefkens Institute, Erasmus MC, Rotterdam, Netherlands;
7
University of Toronto, University Health Network and
Mount Sinai Hospital, Toronto, ON, Canada
Gavin M. Langillle, Binyou Zheng, Dawn L.
MacLellan
Dalhousie University, Halifax, NS, Canada
11:36 a.m.
1
11:18 a.m.
Guimin Chang, Zheng Hu, Jodi K. Maranchie
University of Pittsburgh Medical Center, Pittsburgh, PA,
United States
11:39 a.m.
Carcinogenesis in the Rat
Ching Wang1, Katsumi Imaida2, Taro Iguchi3,
Gabriel P. Haas1
11:21 a.m.
Department of Urology, University of Pittsburgh, Pittsburgh, PA, United States; 2Department of Pharmacology, University of Pittsburgh, Pittsburgh, PA, United
States
1
11:42 a.m.
P25. Soy Isoflavone G-2535 and Bladder
Cancer: Molecular Effects in Tumor
Tissue and Urine
Edward Messing1, KyungMann Kim2, Jason Gee2,
Daniel Saltzstein3, Robert Weiss4, Jorge Yao1,
P. Anthony di'SantAgnese1, Howard Bailey2.
University of Rochester, Rochester, NY, United States;
University of Wisconsin–Madison, Madison, WI,
United States; 3Urology San Antonio, San Antonio, TX,
United States; 4Yale University School of Medicine,
New Haven, CT, United States
McGill University, Montréal, QC, Canada; 2Universite
de Montréal, Montréal, QC, Canada
1
11:45 a.m.
MUHC, Montréal, QC, Canada; 2McGill UniversityMUHC, Montréal, QC, Canada
1
11:48 a.m.
P26. Reconstruction of an Autologous
Urethral Model by Tissue Engineering
Labortoire d'Organogénèse Expérimentale (LOEX),
Quebec, QC, Canada
P27. Effect of Varicocelectomy on Sperm
Chromatin and DNA Integrity
Hospital Clinic, Barcelona, Spain; 2Memorial SloanKettering Cancer Center, New York,, NY, United
States; 3University of Toronto, University Health Network, Toronto, ON, Canada; 4University of Texas,
Southwestern Medical Center, Dallas, TX, United
States
1
Raed Azhar, Abdulaziz Baazeem, Maria San
Gabriel, Armand Zini
McGill University, Montréal, QC, Canada
P28. Pilot Study on WST11 Safety
and Efficacy for Vascular Targeted
Photodynamic Therapy in the
Dog Prostate
Maurice Anidjar1, Eleonora Scarlata1, Lucie
Hamel1, Sabri Moussa1, Konrad Szymanski1,
Mostafa Elhilali1, Avigdor Scherz2, Herve
Ficheux3, Simone Chevalier1.
20
1McGill University Health Center-Research Institute,
Montréal, QC, Canada; 2Weizmann Institute, Rehovot,
Israel; 3STEBA, Paris, France
11:33 a.m.
P29. Regulation of Apoptosis in Renal
Epithelial Cells by Annexin A1 During
Mechanical Stress
P34. Androgen Receptor (AR) and
Bladder Cancer: A Large Bi-Institutional
Study on 473 Patients
Carmen Mic1, Shahrokh Shariat2, Theodorus Van
der Kwast3, Raheela Ashfaq4, Yair Lotan4, Sean
Skeldon3, Sally Hanna3, Sultan AlKhateeb3, Juan
Morote1, Bas Van Rhijn3, Neil Fleshner3, Michael
Jewett3, Alexandre R. Zlotta3
Gabrielle Ouellet, Geneviève Bernard, Stéphane
Bolduc
11:30 a.m.
P33. Peroxiredoxins: Novel Antioxidant
Enzymes of Human Spermatozoa
Angela Souza1, Cristian O'Flaherty2
2
11:27 a.m.
P32. Early Induction of Erectile
Dysfunction by Angiotensin II in the Rat
Robert L. Segal1, Frederic Mampouma2, Taben
M. Hale2, Serge Carrier1, Denis deBlois2
1
11:24 a.m.
P31. Frequency Dependent Pudendal
Neuromodulation and Opiate Receptor
Involvement in the Pudendal-to-Bladder
Reflex in Cats
Mang L. Chen1, Bing Shen2, Jicheng Wang1,
Hailong Liu1, James R. Roppolo2, William C. de
Groat2, Changfeng Tai2
P24. Role of NF-B In Bladder
1SUNY Upstate Medical University, Syracuse, NY,
United States; 2Kagawa University Medical School, Kagawa, Japan; 3Osaka City University Medical School,
Osaka, Japan
P30. Specific NADP(H) Oxidase
Inhibition Abrogates HIF Transactivation
and the Tumorigenic Phenotype of
Renal Cancer Cells
11:51 a.m.
Noon
Noon – 1:30 p.m.
1:30 – 2:45 p.m.
1:30 p.m.
1:35 p.m.
Discussion
Adjourn
Sneak Peek Luncheon in Exhibit Hall
Plenary Session II
Welcome and Introduction
Testosterone Supplementation and
Its Risks
Shahrokh Shariat, Dallas Texas, United States
Panel: Francesco Montorsi, Gerald Brock, Serge
Carrier, Pierre Karakiewicz
Moderators: Peter Chan and Pierre Karakiewicz
Northeastern Section of the AUA — 2009 Annual Meeting
2 p.m.
Prostatitis: A Phoenix Rising from the
Ashes
Khurshid A. Guru1, Thenkurussi Kesavadas2,
Ankur Baheti2, Govindarajan Srimathveeravalli2
J. Curtis Nickel,
1Roswell Park Cancer Institute, Buffalo, NY, United
States; 2State University of New York at Buffalo,
Buffalo, NY, United States
Kingston General Hospital, Kingston, Ontario, Canada
2:45 – 3:15 p.m.
3:15 – 5 p.m.
3:15 – 3:45 p.m.
3:45 – 4 p.m.
4 – 5 p.m.
4 p.m.
Panel: Martine Jolivet-Tremblay, Robert M.
Moldwin and Serge Carrier
Moderators: Bruno Laroche and Jerzy Gajewski
Break in Exhibit Hall
Concurrent Poster Sessions
View Posters
Welcome and Introduction
Moderated Poster Session III:
Robotics, Endoscopy and
Laparoscopy
Moderator: Hassan Razvi and Barry Kogan
P35. A Multi-Centre Randomized Trial
Comparing Bipolar vs. Monopolar
Transurethral Resection of the Prostate
4:15 p.m.
Matthew M. Lux, Jorge Yao, Jean V. Joseph
University of Rochester, Rochester, NY, United States
4:18 p.m.
University of Rochester, Rochester, NY, United States
4:21 p.m.
Schulich School of Medicine and Dentistry, London,
ON, Canada
Claudio Jeldres1, Hendrik Isbarn2, Umberto
Capitanio3, Laurent Zini4, Naeem Bhojani5,
Shahrokh F. Shariat5, Vincent Cloutier4,
Jean-Baptiste Lattouf5, Alain Duclos5, Martine
Jolivet-Tremblay5, Luc Valiquette5, Fred Saad1,
Markus Graefen2, Francesco Montorsi3, Paul
Perrotte5, Pierre I. Karakiewicz1
University of Montréal Health Center, Montréal, QC,
Canada; 2Prostate Cancer Center Hamburg-Eppendorf,
Hamburg, Germany; 3Vita-Salute San Raffaele, Milan,
Italy; 4Lille University Hospital, Lille, France; 5University
of Montréal, Montréal, QC, Canada
1
4:06 p.m.
Roswell Park Cancer Institute, Buffalo, NY, United
States
4:24 p.m.
University of Montréal, Montréal, QC, Canada
4:27 p.m.
Jeffrey J. Tomaszewski, Marc C. Smaldone,
Stephen V. Jackman, Timothy D. Averch
University of Rochester, Rochester, NY, United States;
Rochester General Hospital, Rochester, NY, United
States
1
2
4:30 p.m.
P38. Validation of Real-Time, Intra-
Operative, Surgical Competence
(RISC) Assessments Linked to
Patient Outcomes
McMaster University, Hamilton, ON, Canada
University of Toronto, Toronto, ON, Canada
P39. Can Human Anatomy be Taught
Through the Lenses of a Virtual Reality
Simulator?
P45. The Value of Transrectal Ultrasound
in Predicting Prostate Weights and Outcomes Following Laparoscopic Radical
Prostatectomy
Jason Kovac, Adeel Sheikh, Ayman Raees,
Bobby Shayegan, John P. Whelan, Edward D.
Matsumoto
Ethan D. Grober, Matthew Roberts, Mohammed
Mahdi, Wonnie Shin, Michael AS Jewett
4:12 p.m.
P44. Robotic-Assisted Transvesical
Prostatectomy for Benign Prostatic
Hypertrophy: Description of Technique
and Operative and Post-Operative Data
of Initial Series of Six Patients
Allison L. Cardin1, Eric A. Singer1, Jonah
Marshall1, Dragan Golijanin1, John Valvo2,
Louis Eichel2, Frederick Tonetti2
Radiologist During Percutaneous
Nephrolithotomy
4:09 p.m.
P43. Laparoscopic Nephroureterectomy
Does Not Undermine Cancer Control
Outcomes in Selected Patients with
Non-metastatic Upper Tract Urothelial
Carcinoma: A Multi-Institutional Analysis
of 1249 Cases
Al'a Abdo, Claudio Jeldres, Naeem Bhojani,
Daniel Liberman, Fred Saad, Francois Benard,
Luc Valiquette, Paul Perrotte, Pierre I.
Karakiewicz
P37. Renal Access by Urologist or
University of Pittsburgh School of Medicine,
Pittsburgh, PA, United States
P42. Simplified Laparoscopic Partial
Nephrectomy Using a Single-Layer
Closure and No Bolsters for Central
Renal Tumors
Matthew Hayn, Khurshid Guru, Hyung Kim
P36. Development and External
Validation of a Highly Accurate
Nomogram for the Prediction of
Perioperative Mortality After
Transurethral Resection of the Prostate
for Benign Prostatic Hyperplasia
P41. Does Obesity Affect Outcomes in
Extraperitoneal Robot-Assisted
Prostatectomies?
Matthew M. Lux, Tricia D. Greene, Jean V.
Joseph
Carlos E. Mendez Probst, Linda Nott,
Hassan Razvi
4:03 p.m.
P40. Does Prostate Size Matter? An
Evaluation of Patients Undergoing
Robot-Assisted Prostatectomy
4:33 p.m.
P46. Robotics in Urology: Comparative
International Contemporary Practice
Patterns
21
Bertram Yuh1, Rameela Chandrasekhar2, Abid
Hussain2, Gregory Wilding2, James Mohler2, Mani
Menon3, James Peabody3, Khurshid Guru2
4:03 p.m.
University of Buffalo, Buffalo, NY, United States;
Roswell Park Cancer Institute, Buffalo, NY, United
States; 3Henry Ford Hospital, Detroit, MI, United States
1
Jose Mansure, Roland Nassim, Simone
Chevalier, Joice Rocha, Eleonora
Scarlata, Wassim Kassouf
2
Current Status of Robot-Assisted
Surgery in Urology: A Multi-National
Survey of 297 Urologic Surgeons
McGill University Health Center, Montréal, QC, Canada
4:06 p.m.
Khurshid A. Guru1, Rameela Chandrasekhar2,
Abid Hussain1, Pamela Piacente1, Marlene
Bienko1, Mark Glasgow2, Willie Underwood1,
Gregory Wilding2, James L. Mohler1, Mani
Menon3, James O. Peabody,3
1Roswell Park Cancer Institute, Buffalo, NY, United
States; 2State University of New York at Buffalo, Buffalo, NY, United States; 3Vattikuti Urology Institute,
Henry Ford Hospital, Detroit, MI, United States
4:36 p.m.
P47. Comparison of Extraperitoneal and
University of Montréal, Montréal, QC, Canada;
Vita Salute University San Raffaele, Milan, Italy
1
2
4:09 p.m.
P48. Early Post-Operative Renal
Tants University, Tanta, Egypt
4:12 p.m.
Scintigraphy as a Predictor of LongTerm Outcomes After Laparoscopic
Pyeloplasties
1Centre Hospitalier Universitaire de Quebec, Québec,
QC, Canada; 2Université Laval, Québec, QC, Canada
P49. From Laparoscopic to RoboticAssisted Pyeloplasty: Our Extended
Experience
Bishoy A. Gayed, Bruce L. Jacobs, Tina K.
Schuster, Timothy D. Averch
University of Montréal, Montréal, QC, Canada; 2VitaSalute San Raffaele, Milan, Italy; 3Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany
1
4:15 p.m.
University of Pittsburgh, Pittsburgh, PA, United States
4:45 p.m.
5 p.m.
4 – 5 p.m.
4 p.m.
22
P55. Stage Distribution at Radical Cystectomy During the Last Two Decades
Al'a Abdo, Claudio Jeldres, Daniel Liberman,
Naeem Bhojani, Fred Saad, Luc Valiquette, Paul
Perrotte, Pierre I. Karakiewicz
Discussion
Adjourn
Moderated Poster Session IV:
Bladder Cancer
Moderators: Paul Perrotte and
Alexandre R. Zlotta
P50. A Comparative Survival Analyses of
4:18 p.m.
Nonbilharzial Squamous Cell Carcinoma
vs. Transitional Cell Carcinoma After
Radical Cystectomy
4:21 p.m.
Nawar Hanna1, Claudio Jeldres1, Sara
Baillargeon-Gagne1, Hendrik Isbarn1, Umberto
Capitanio1, Shahrokh F. Shariat1, Giovanni
Lughezzani1, Maxine Sun1, Fred Saad1, Paul
Perrotte1, Francesco Montorsi2, Markus Graefen3,
Pierre I. Karakiewicz1
P54. A Population-Based Assessment of
Perioperative Mortality After Cystectomy
for Bladder Cancer
Claudio Jeldres1, Hendrik Isbarn1, Laurent Zini1,
Paul Perrotte1, Sara Baillargeon-Gagne1,
Umberto Capitanio1, Shahrokh F. Shariat1,
Philippe Arjane1, Fred Saad1, Michael
McCormack1, Luc Valiquette1, Francois Peloquin1,
Alain Duclos1, Francesco Montorsi2, Markus
Graefen3, Pierre I. Karakiewicz1
Michel Hugues Lebel1, Frederic Pouliot1, David
Méthot-Langevin2, Jean-François Audet1, Thierry
Dujardin1
4:42 p.m.
P53. Combined Modality Treatment with
Bladder Preservation for Muscle Invasive
Bladder Cancer
Magdy A. Sabaa Sr.
Matthew M. Lux, Erdal Erturk, Jean V. Joseph
4:39 p.m.
P52. A Comparative Survival Analysis of
Adenocarcinoma vs. Transitional Cell
Carcinoma After Radical Cystectomy
Radoslav Krouchev1, Giovanni Lughezzani1,
Claudio Jeldres1, Sara Baillargeon-Gagne1,
Hendrik Isbarn1, Daniel Liberman1, Paul Perrotte1,
Fred Saad1, Luc Valiquette1, Francesco Montorsi2,
Pierre I. Karakiewicz1
Transperitoneal Robot-Assisted Radical
Prostatectomy in the Obese Patient
University of Rochester, Rochester, NY, United States
P51. mTOR Inhibitor RAD001
(everolimus) Has Significant Antitumor
Activity in Bladder Cancer
University of Montréal, Montréal, QC, Canada
P56. The Incidence of Prostate Cancer
and Urothelial Cancer in the Prostate in
Cystoprostatectomy Specimens
Sri Sivalingam, Darrel Drachenberg
University of Manitoba, Winnipeg, MB, Canada
P57. Management and Outcome of
Patients Who Had Unresectable Disease
Upon Exploratory Laparotomy for
Bladder Cancer
Faysal A. Yafi, Marie Duclos, José A. Correa,
Simon Tanguay, Armen G. Aprikian, Fabio Cury,
Luis Souhami, Raghu Rajan, Wassim Kassouf
McGill University, Montréal, QC, Canada
University of Montréal, Montréal, QC, Canada;
2Vita-Salute San Raffaele, Milan, Italy; 3Martiniclinic,
Prostate Cancer Center Hamburg-Eppendorf,
Hamburg, Germany
1
Northeastern Section of the AUA — 2009 Annual Meeting
4:24 p.m.
P58. Impact of Sub-Stage and Pathology
Faysal A. Yafi1, Armen G. Aprikian1, Yves Fradet2,
Joe Chin3, Jonathan Izawa3, Ricardo Rendon4,
Eric Estey5, Adriane Fairey5, Ilias Cagiannos6,
Louis Lacombe2, Jean-Baptiste Lattouf7, David
Bell4, Darrel Drachenberg8, Wassim Kassouf1
Review on the Clinical Outcome of pT1
Bladder Cancer
Bas W. G. van Rhijn1, Theo H. van der Kwast1,
David Kakiashvili1, Neil E. Fleshner1, Sultan
Alkhateeb1, Madelon N. M. van der Aa2, Rati
Vajpeyi3, Chris H. Bangma2, Michael A. S.
Jewett1, Alexandre R. Zlotta1
1McGill University, Montréal, QC, Canada, 2Laval University, Quebec, QC, Canada; 3University of Western
Ontario, London, ON, Canada; 4Dalhousie University,
Halifax, NS, Canada; 5University of Alberta, Edmonton,
AB, Canada; 6University of Ottawa, Ottawa, ON,
Canada; 7University of Montréal, Montréal, QC,
Canada; 8University of Manitoba, Winnipeg, MB,
Canada
1University of Toronto, University Health Network,
Toronto, ON, Canada; 2Josephine Nefkens Institute,
Erasmus MC, Rotterdam, Netherlands; 3University
Health Network, Toronto, ON, Canada
4:27 p.m.
P59. Long-term Follow-Up for Primary
4:42 p.m.
T1 High-Grade Bladder Cancer—Does
BCG Really Prevent Progression?
David Kakiashvili1, Bas W. G. van Rhijn1, Michael
A. S. Jewett1, Neil E. Fleshner1, Julian Azzuero1,
Alex Kostynskyy2, Chris H. Bangma3, Theodorus
H. Van Der Kwast1, Alexandre R. Zlotta1
Edward Messing1, Yves Fradet2, Alvaro
Morales3, Lance Mynderse4, Mark Soloway5,
Unyime Nseyo6, Seth Lerner7, H. Barton
Grossman8
1University of Toronto, University Health Network,
Toronto, ON, Canada; 2University Health Network,
Toronto, ON, Canada; 3Josephine Nefkens Institute,
Erasmus MC, Rotterdam, Netherlands
4:30 p.m.
University of Rochester, Rochester, NY, United States;
U'Laval University, Quebec, QC, Canada; 3Kingston
General Hospital, Kingston, ON, Canada; 4Mayo Clinic,
Rochester, MN, United States; 5University of Miami,
Miami, FL, United States; 6University of Florida,
Gainesville, FL, United States; 7Baylor College of Medicine, Houston, TX, United States; 8MD Anderson,
Houston, TX, United States
1
2
P60. What Is the Long-Term Prognostic
Value of Pro-Apoptotic, Anti-Apoptotic,
Proliferation and Invasiveness Molecular
Markers in Patients Treated with BCG for
High Risk Non-Muscle Invasive Bladder
Cancer?
S. Alkhateeb1, MG Neill1, B. Van Rhijn1, D.
Kakiashvili1, N. Fleshner1, M. Jewett1, S.
Bar-Moshe2, M. Petein2, C. Schulman2, T.
Roumeguere2, S. Rorive2, Alexandre R. Zlotta1
University of Toronto, University Health Network,
Toronto, ON, Canada; 2Erasme Hospital and University
Clinics of Brussels, Brussels, Belgium
4:45 p.m.
McGill University, Montréal, QC, Canada
4:48 p.m.
P61. Does Screening for Bladder Cancer
Produce a Stage Migration Towards
Non-Muscle Invasive Cancers?
Alexandre R. Zlotta1, T. Roumeguere2,
S. Alkhateeb1, S. Rorive2, A. Lemy2, I. Salmon2,
M. Wissing2, D. Abramowicz2, C. Schulman2,
N. Fleshner1, M. Jewett1, J. Nortier2
University of Toronto, University Health Network,
Toronto, ON, Canada; 2Erasme Hospital and University
Clinics of Brussels, Brussels, Belgium
P62. Cost Analysis of a Single Instillation
of Mitomycin C after Transurethral
Resection of Bladder Tumor in the
Quebec Health Care System
P66. Combining mTOR Inhibitor
(RAD001) with Ionizing Radiation: A
Novel Strategy for the Treatment of
Bladder Cancer
Roland Nassim1, Jose Joao Mansure2, Simone
Chevalier1, Fabio Cury2, Wamied Abdul Rahman2,
Ismail Al-Dahlawi2, Wassim Kassouf1
McGill University, Montréal, QC, Canada; 2McGill
University Health Center, Montréal, QC, Canada
1
1
4:36 p.m.
P65. Survey on the Work-Up and
Screening of Hematuria Among General
Practitioners in Quebec
Faysal A. Yafi, Armen G. Aprikian, Simon
Tanguay, Wassim Kassouf
1
4:33 p.m.
P64. Florescence Cystoscopy with Hexaminolevulinate (HAL) Improves Detection Rate of Ta and T1 Bladder Cancer
and Reduces Recurrence Following
TURBT at Nine Months
4:51 p.m.
5 p.m.
5:30 – 6:30 p.m.
7 – 9 p.m.
Discussion
Adjourn
Exhibit Hall Grand Opening/Welcome
Reception
Networking Reception
Robert L. Segal, Andrew Feifer, Xuanqian Xie,
James M. Brophy, Wassim Kassouf
McGill University, Montréal, QC, Canada
4:39 p.m.
P63. Surveillance Guidelines Based on
Recurrence Patterns Following Radical
Cystectomy for Bladder Cancer: The
Canadian Bladder Cancer Network
Experience
23
FRIDAY, OCTOBER 9, 2009
6 – 7:30 a.m.
11:03 a.m.
New Treatments for Erectile Dysfunction
Following Radical Prostatectomy: Focus
on Soft Glans Challenges
J. Letendre, D. Barrieras, A.M. Houle, K. Keu, R.
Lambert, S. Turpin, J. Franc-Guimond
Andrew R. McCullough
New York University School of Medicine, New York,
NY, United States
Sponsored by VIVUS, Inc.
6:30 – 8 a.m.
7:30 – 7:45 a.m.
7:45 – 8:45 a.m.
7:45 a.m.
8:15 a.m.
8:45 – 9:45 a.m.
8:45 a.m.
CHU Sainte-Justine, Montréal, QC, Canada
11:06 a.m.
Laval University, Québec, QC, Canada
11:09 a.m.
Plenary Session III:
Section Stars
Moderator: Anne-Marie Houle
Prize Essay Winners: P27, P31 and P81
Past NS-AUA Young Investigator
Grant Recipients
Anthony J. Bella (2007 Recipient)
University of Ottawa
Ottawa, ON Canada
Molecular Mechanisms of Cavernous Nerve
Regeneration Following Prostate Cancer
Treatment in men with Metabolic Syndrome Update
Jehonathan Pinthus (2008 Recipient)
Juravinski Cancer Center-Hamilton Health
Sciences
Hamilton, OH Canada
Obesity and RCC- the Adiponectin Axis as a
Link
Plenary Session IV
Montréal Children’s Hospital, Montréal, QC, Canada
11:12 a.m.
Université Laval, Québec, QC, Canada
11:15 a.m.
Hypospadias Repair: A Series of 161
Patients
24
Marie-Pier Deschênes Rompré, Katherine
Moore, Stéphane Bolduc
Université Laval, Québec, QC, Canada
P72. Solifenacin for Overactive Bladder
in Children: A Prospective Open-Label
Study
Stéphane Bolduc, Katherine Moore
CHUL, Québec, QC, Canada
11:18 a.m.
P73. Percutaneous Management of
Urolithiasis in Children and Adolescents
with Spinal Cord Lesions
Bishoy A. Gayed, Marc C. Smaldone,
Michael C. Ost
Cleveland Clinic, Cleveland, Ohio, United States
Panelists: Edward Messing, John M. Fitzpatrick,
and Alexandre R. Zlotta
Moderator: Pierre Karakiewicz
9:45 – 10:15 a.m. Break in Exhibit Hall
10:15 a.m. – Noon Concurrent Poster Sessions
10:15 – 10:45 a.m. View Posters
10:45 – 11 a.m.
Welcome and Introduction
11 a.m. – Noon
Moderated Poster Session V:
Pediatric Urology
Moderators: Philip G. Ransley and
Anne-Marie Houle
11 a.m.
P67. TIP Urethroplasty in Primary
P71. Study on Hydrophilic-Coated
Catheter Appreciation in a Pediatric
Population
Andréanne Boucher, Jonathan Cloutier, Sylvie
Lebel, Micheline Hamel, Pascale Lamontagne,
Stéphane Bolduc
Eric A. Klein
Universitá Vita Salute, Milan, Italy
P70. Dye-Assisted Lymphatic-Sparing
Laparoscopic Varicocelectomy in
Children: Initial Experience
Waleed Eassa, Mohammed El-Sherbiny, Roman
Jednak, John-Paul Capolicchio
PSA Screening
Francesco Montorsi
P69. Study Comparing the Applicability
of Dorsal Lumbotomy in Older Children
Jonathan Cloutier, Nadim Haidar, Marie-Pier
Rompré, Maryse Grimard, Stephane Bolduc
5K Run/Walk
Best-of-Poster Sessions
Presented by moderators of previous
day’s poster sessions
P68. Assessing Ureteropelvic Junction
Obstruction (UPJO) Using Original
Renographic Criteria for a Decade
Proves to be Reliable
Industry-Sponsored Breakfast
Symposium
University of Pittsburgh, Pittsburgh, PA, United States
11:21 a.m.
P74. Ethical Considerations in the
Management of Cryptorchidism in the
Profoundly Disabled
Eric A. Singer, Danielle R. Wendel, Nadia A.
Awad, Richard A. Demme, Jane Greenlaw,
William C. Hulbert, Jr., Robert A. Mevorach,
Ronald Rabinowitz
University of Rochester Medical Center, Rochester,
NY, United States
11:24 a.m.
P75. High Cost, Minimal Benefit: A
Cost-Benefit Analysis of Ultrasound in
the Management of Adolescent
Varicocele
Adam Walker, Barry Kogan
Albany Medical Center, Albany, NY, United States
11:27 a.m.
P76. Can We Avoid Removing the
Adrenal Gland at the Time of Radical
Nephrectomy in Children with Wilms
Tumor?
Northeastern Section of the AUA — 2009 Annual Meeting
Armando J. Lorenzo1, Katherine Moore1, Bruno
Leslie1, Stephane Bolduc2
Hospital for Sick Children, Toronto, ON, Canada;
Centre Hospitalier Universitaire de Québec, Quebec,
QC, Canada
11a.m. – Noon
1
2
11:30 a.m.
11 a.m.
Migration in Surgically-Treated Patients
with Upper Urinary Tract Transitional Cell
Carcinoma
P77. Are There Risk Factors for Perinatal
Torsion?
Lei Chu, Michael C. Ost, Steven G. Docimo,
Mark F. Bellinger, Francis X. Schneck
P78. Evaluation of Hydronephrosis in
Pediatric Kidney Transplants and its
Clinical Relevance
Giovanni Lughezzani1, Claudio Jeldres1, Hendrik
Isbarn1, Maxine Sun1, Shahrokh F. Shariat1,
Daniel Liberman1, Hugues Widmer1, Philippe
Arjane1, Daniel Pharand1, Markus Graefen2,
Paul Perrotte1, Francesco Montorsi3, Pierre I.
Karakiewicz1
Lei Chu, Bruce L. Jacobs, Michael C. Ost, Mark
F. Bellinger, Steven G. Docimo, Francis X.
Schneck
University of Montréal, Montréal, QC, Canada;
Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany; 3Vita-Salute University, Milan, Italy
University of Pittsburgh, Pittsburgh, PA, United States
11:33 a.m.
University of Pittsburgh, Pittsburgh, PA, United States
11:36 a.m.
1
2
11:03 a.m.
P79. Retroperitoneoscopic Nephrectomy
in Children on Peritoneal Dialysis: The
Gold Standard
Montréal Children’s Hospital, Montréal, QC, Canada
P80. Long-Term Functional Outcome
After Primary Repair of Classic Bladder
Exstrophy
University of Montréal, Montréal, QC, Canada;
Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany; 3Vita-Salute University, Milan, Italy
1
Waleed Eassa, Roman Jednak, John Paul
Capolicchio, Mohamed T. El Sherbiny
Montréal Children’s Hospital, Montréal, QC, Canada
11:42 a.m.
P81. In Vitro Reconstruction of an
2
11:06 a.m.
Autologous, Watertight and Resistant
Vesical Equivalent
Stéphane Bolduc
P82. Serosal Lined Extramural Tunnel
Principle in the Creation of a
Catheterizable Channel in Bladder
Augmentation: The Video
Mohamed T. El Sherbiny, Waleed Eassa
University of Montréal, Montréal, QC, Canada;
Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany; 3Vita-Salute San Raffaele, Milan, Italy
1
2
11:09 a.m.
Montréal Children’s Hospital, Montréal, QC, Canada
11:48 a.m.
P83. Dextranomer/Hyaluronic Acid
Copolymer (Deflux) Injections in a
Teaching Center: The Real Picture
CHU Sainte-Justine, Montréal, QC, Canada
P84. The Anterior Approach to
Retroperitoneoscopic Adrenalectomy in
Children
Waleed Eassa, Mohammed El-Sherbiny, Roman
Jednak, John-Paul Capolicchio
Montréal Children’s Hospital, Montréal, QC, Canada
11:54 a.m.
Noon
Discussion
Adjourn
P88. The Impact of Tumor Stage and
Nodal Metastases on Cancer Specific
Mortality in Patients with Upper Urinary
Tract Transitional Cell Carcinoma: Results from a Population-Based Study
Giovanni Lughezzani1, Claudio Jeldres1, Hendrik
Isbarn1, Maxine Sun1, Shahrokh F. Shariat1,
Daniel Pharand1, Hugues Widmer1, Philippe
Arjane1, Markus Graefen2, Paul Perrotte1,
Francesco Montorsi3, Pierre I. Karakiewicz1
Julie Franc-Guimond, Julien Letendre, Diego
Barrieras, Anne-Marie Houle
11:51 a.m.
P87. Segmental Ureterectomy Can
Safely Be Performed in Patients with
Ureteral Upper Tract-Transitional Cell
Carcinoma
Daniel Liberman1, Claudio Jeldres1, Giovanni
Lughezzani1, Hendrik Isbarn1, Maxine Sun1,
Shahrokh F. Shariat1, Daniel Pharand1, Philippe
Arjane1, Margit Fisch2, Markus Graefen2,
Francesco Montorsi3, Paul Perrotte1, Pierre I.
Karakiewicz1
Laval University, Quebec, QC, Canada
Sara Bouhout, Émilie Perron, Robert Gauvin, Geneviève
Bernard and Stéphane Bolduc
Laval University, Quevec, QC, Canada
11:45 a.m.
P86. An Assessment of the Prognostic
Significance of Tumor Grade in Patients
with Upper Urinary Tract Transitional Cell
Carcinoma: A Population-Based Study
Giovanni Lughezzani1, Claudio Jeldres1, Hendrik
Isbarn1, Maxine Sun1, Shahrokh F. Shariat1,
Daniel Pharand1, Hugues Widmer1, Philippe
Arjane1, Markus Graefen2, Francesco
Montorsisale3, Paul Perrotte1, Pierre I.
Karakiewicz1
Konrad M. Szymanski, Martin Bitzan, John-Paul
Capolicchio
11:39 a.m.
Moderated Poster Session VI:
Oncology
Moderator: Pierre Karakiewicz
P85. Temporal Stage and Grade
University of Montréal, Montréal, QC, Canada;
Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany; 3Vita-Salute University, Milan, Italy
1
2
11:12 a.m.
P89. Patients with Renal Pelvis Upper
Tract Transitional Cell Carcinoma Have
Significantly Worse Cancer-Specific Survival than Patients with Ureteral Primaries
25
Daniel Liberman1, Claudio Jeldres1, Al'a Abdo1,
Fred Saad1, Francois Benard1, Luc Valiquette1,
Francesco Montorsi2, Paul Perrotte1, Pierre I.
Karakiewicz1
Claudio Jeldres1, Maxine Sun1, Hendrik Isbarn1,
Giovanni Lughezzani1, Shahrokh F. Shariat1,
Daniel Pharand1, Hugues Widmer1, Philippe
Arjane1, Francesco Montorsi2, Paul Perrotte1,
Pierre I. Karakiewicz1
University of Montréal, Montréal, QC, Canada;
Vita-Salute San Raffaele, Milan, Italy
1
11:15 a.m.
2
1
P90. A Population-Based Assessment
2
of Perioperative Mortality After
Nephroureterectomy for Upper-Tract
Transitional Cell Carcinoma
Claudio Jeldres1, Maxine Sun1, Hendrik Isbarn1,
Giovanni Lughezzani1, Shahrokh F. Shariat1,
Daniel Liberman1, Hugues Widmer1, Daniel
Pharand1, Philippe Arjane1, Markus Graefen2,
Francesco Montorsi3, Paul Perrotte1, Pierre I.
Karakiewicz1
University of Montréal, Montréal, QC, Canada;
Vita-Salute San Raffaele, Milan, Italy
11:30 a.m.
Geneviève Nadeau, François Harel, Pierre
Douville, Yves Fradet, Louis Lacombe
Laval University, Quebec, QC, Canada
11:33 a.m.
University of Montréal, Montréal, QC, Canada;
Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany; 3Vita-Salute San Raffaele, Milan, Italy
1
2
11:18 a.m.
Valerie Deslauriers1, Giovanni Lughezzani1,
Hendrik Isbarn1, Claudio Jeldres1, Maxine Sun1,
Shahrokh F. Shariat1, Daniel Pharand1, Hugues
Widmer1, Philippe Arjane1, Markus Graefen2, Paul
Perrotte1, Francesco Montorsi3, Pierre I.
Karakiewicz1
University of Pittsburgh School of Medicine,
Pittsburgh, PA, United States
11:36 a.m.
University of Pittsburgh School of Medicine,
Pittsburgh, PA, United States
11:39 a.m.
University of Montréal, Montréal, QC, Canada;
Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany; 3Vita-Salute University, Milan, Italy
2
P92. Significance of Positive Bladder
Cuff in Nephroureterectomy Specimen in
Patients with Upper Urinary Tract
Urethelial Tumors
Yasser Osman, Mohamed El Awady, Mahmoud
Kenawy, Mohamed Gaballa, El-Housseiny
Ibrahiem
1The Urological Institute of Northeastern New York,
Albany, NY, United States; 2GTx, Inc, Memphis, TN,
United States
11:42 a.m.
Post-Nephroureterctomy for Upper
Urinary Tract-Urothelial Carcinoma,
Analysis of Risk Factors
McGill University, Montréal, QC, Canada
11:45 a.m.
26
P94. Development and External
Validation of a Highly Accurate
Nomogram for the Prediction of
Cancer-Specific Mortality After
Nephroureterectomy for Upper Tract
Transitional Cell Carcinoma
P100. Comparison of the Costs of Active
Surveillance vs. Radical Prostatectomy
Anthony T. Corcoran, Ronald M. Benoit
University of Pittsburgh Medical Center, Pittsburgh, PA,
United States
Mansoura Urology and Nephrology Center, Mansoura,
Egypt
11:27 a.m.
P99. Retroperitoneal Lymph Node
Dissection of Post-Chemotherapy
Residual Masses for Metastatic
Germ Cell Testicular Cancer
Murilo A. Luz, Simon Tanguay, Wassim Kassouf,
Ahmed F. Kotb, Saad Aldousari, Armen G.
Aprikian
P93. Intravesical Recurrence
Yasser Osman, Mohamed El Awady, Mahmoud
Kenawy, Mohamed Gaballa, El-Housseiny
Ibrahiem
P98. Toremifene 80 Mg Phase 3 Trial
in Men on ADT Demonstrates
Improvement in Gynecomastia
Compared to Placebo.
Hugh Fisher1, Ronald Kaufman1, Ronald A.
Morton2.
Mansoura Urology and Nephrology Center,
Mansoura, Egypt
11:24 a.m.
P97. Treatment and Outcomes of
Bladder Cancer Following Solid Organ
Transplantation
Jeffrey J. Tomaszewski, Jeff Larson, Marc C.
Smaldone, Stephen V. Jackman
1
11:21 a.m.
P96. Cesium-131 Versus Iodine-125
Implants for Prostate Cancer: Evaluation
of Early PSA Response
Jeffrey J. Tomaszewski, Marc C. Smaldone,
Ronald M. Benoit
P91. Gender-Related Differences in
Patients with Upper Urinary Tract
Transitional Cell Carcinoma: Results
from the Surveillance, Epidemiology
and End Results Database
P95. Prognostic Value of Insulin-Like
Growth Factor-I and Binding Proteins 2
and 3 in Patients Treated with Radical
Prostatectomy
11:48 a.m.
P101. Phase III Trial in Men on ADT
Demonstrates a Reduction in Hot
Flashes in Men on Toremifene 80 mg
Compared to Placebo
Jeff Gingrich1, Philip Aliotta2, Ronald A. Morton3
Pittsburgh VA Health Care Center, Pittsburgh, PA,
1
Northeastern Section of the AUA — 2009 Annual Meeting
United States; 2Center for Urologic Reseach of WNY,
LLC, Williamsville, NY, United States; 3GTx, Inc,
Memphis, TN, United States
11:51 a.m.
Noon
1:15 – 3 p.m.
1:15 p.m.
1:20 p.m.
Discussion
Adjourn
Plenary Session V
1Watson Laboratories, Inc, Salt Lake City, UT, United
States; 2Urology Associates/Urology Medical
Research, Kitchner, ON, Canada
4:15 p.m.
Welcome and Introduction
Prostate Cancer Chemo Prevention
P107. Utility of an Ambulatory Pessary
Trial to Unmask Occult Stress Urinary
Incontinence
Bilal Chughtai, Elise J. B. De
Albany Medical Center, Albany, NY, United States
Eric A. Klein, Cleveland Clinic, Cleveland, Ohio,
United States
4:18 p.m.
Panelists: John Fitzpatrick and Alexandre Zlotta
Moderator: Shahrokh Shariat
2:15 p.m.
AUA Course of Choice: Interstitial
Cystitis/Painful Bladder Syndrome
and Related Conditions: Practical
Management Strategies
Andrew R. McCullough, Brianne Goodwin,
Herbert Lepor
Moderator: Luc Valiquette
Robert Moldwin
New York University School of Medicine, New York,
NY, United States
Smith Institute of Urology, New Hyde Park, New York
3:30 – 5 p.m.
3:30 – 3:45 p.m.
3:45 – 4 p.m.
4 – 5 p.m.
4 p.m.
Concurrent Poster Sessions
View Posters
Welcome and Introduction
Moderated Poster Session VII:
General Urology
Moderators: Peter Chan and J. Curtis Nickel
P102. Research in Urology: A National
4:21 p.m.
University of Rochester, Rochester, NY, United States
4:24 p.m.
Jason Izard, D. Robert Siemens
P103. Suprasacral Spinal Cord Injury
Laval, Quebec, QC, Canada
4:27 p.m.
John M. Rutkowski, Kevan Pranikoff, Jan
Capuana
Queen's University, Kingston, ON, Canada; 2Cleveland
Clinic, Cleveland, OH, United States
1
P104. Surgical Treatment of Bladder
Outlet Obstruction Improves Outcome in
Male Interstitial Cystitis
4:30 p.m.
Roger E. Vega
UPMC St. Margaret, Pittsburgh, PA, United States
4:09 p.m.
Centre Hospitalier Universitaire de Sherbrooke
(CHUS), Sherbrooke, QC, Canada
4:33 p.m.
Emmanuel O. Abara1, Sylvia Naughton2, Oge
Abara3, Rob Williams4
York Central Hospital, Richmond Hill, ON, Canada;
Ontario Telemedicine Network, Barrie, ON, Canada;
3University of Toronto, Toronto, ON, Canada; 4Ontario
Telemedicine Network, Timmins, ON, Canada
1
2
4:12 p.m.
Laboratoire d’Organogénèse expérimentale/LOEX,
CHA, Hôpital du St-Sacrement, Québec, QC, Canada
®
1
2
Keshava N. Kumar , Blair R. Egerdie , Weining
Volinn1, Lawrence Hill1, Gary Hoel
P113. An Autologous Tissue-Engineered
Endothelialized Graft: A Possible Option
in the Surgical Correction of Peyronie’s
Disease
Annie Imbeault, Geneviève Bernard, Gabrielle
Ouellet, Sara Bouhout, Stéphane Bolduc
P106. An Open-Label, Multi-Center
Pharmacokinetic Study of Uracyst
400 mg Following a Single Bladder
Instillation in Subjects with Interstitial
Cystitis/Painful Bladder Syndrome
P112. Mid-Term Results of Pelvic Organ
Prolapse Repair Using a Transvaginal
Mesh: The Sherbrooke Experience
Louis-Olivier Gagnon, Le-Mai Tu
P105. Office-Based Urotelehealth—
Bringing Urology Health Care Near to
Home: A Work in Progress
P111. Clinical Phenotyping of Urologic
Chronic Pelvic Pain Syndromes (UCPPS):
Validation of the “Snowflake Hypothesis”
J. Curtis Nickel1, Daniel Shoskes2
University at Buffalo, Buffalo, NY, United States
4:06 p.m.
P110. A Comparison Between
Composix™-Based Slings, Tension Free
Vaginal Tapes Tvt™ and Transobturator
Tapes Tvt-o™ at a Median Follow-Up of
24 months
Nadim H. Haidar, Katherine Moore, Rachel
Sweenor, Mireille Grégoire
Kingston General Hospital, Kingston, ON, Canada
Patients Managed by Reflex Voiding:
Characterization of our Cohort
P109. The Impact of Clomiphene Citrate
on Severe Idiopathic Oligospermia
Jennifer Gordetsky, Jeanne O'Brien
Survey on Attitudes and Experience of
Research in Urology Residency
4:03 p.m.
P108. The Longitudinal Effects on Penile
Oxygen Saturation from a Prospective
Randomized Study of the Nightly Use of
Intraurethral Alprostadil vs. Sildenafil
Following Nerve-Sparing Radical
Prostatectomy (NSRP)
4:36 p.m.
P114. Chondroitin Sulfate Is a Promising
Therapy for Interstitial Cystitis/Painful
Bladder Syndrome (IC/PBS)
J. Curtis Nickel1, Blair Egerdie2, Anthony
Skehan3, Karen Irvine-Bird1, Joe Downey1
Queen's University, Kingston, ON, Canada; 2Urology
1
27
Associates/Urology Medical Research, Kitchener, ON,
Canada; 3Urology, Thunder Bay, ON, Canada
4:39 p.m.
4:06 p.m.
P115. MRI-Guided Transurethral
Ultrasound Therapy with Real Time
Thermal Mapping: Initial Studies
Brian Kim1, Luke Lavallee1, Dean Fergusson2,
Ilias Cagiannos1
Laurence Klotz, Kashif Siddiqui, Rajif Chopra,
Michael Bronskill.
University of Ottawa, Ottawa, ON, Canada; 2Ottawa
Health Research Institute, Ottawa, ON, Canada
1
Sunnybrook HSC, Toronto, ON, Canada.
4:42 p.m.
P116. Recovery of Erectile Function
4:09 p.m.
Following Nerve-Sparing Radical
Prostatectomy After Penile Rehabilitation
with Nightly Intraurethral Alprostadil vs.
Sildenafil Citrate
New York University School of Medicine, New York,
NY, United States; 2University of Texas–MD Anderson
Cancer Center and University of Texas Medical School,
Houston, TX, United States; 3Texas A & M Health Science Center College of Medicine, Temple, TX, United
States; 4Tulane University, New Orleans, LA, United
States; 5George Washington University, Washington
DC, United States
4:45 p.m.
P117. Provider Recommendation and
McGill University Health Centre (MUHC), Montréal
General Hospital (MGH), Montréal, QC, Canada
4:12 p.m.
Roswell Park Cancer Institute, Buffalo, NY, United States
4:15 p.m.
Giovanni Lughezzani1, Claudio Jeldres1, Hendrik
Isbarn1, Paul Perrotte1, Shahrokh F. Shariat1,
Maxine Sun1, Hugues Widmer1, Philippe Arjane1,
Francois Peloquin1, Saniel Pharand1, Jean-Jaques
Patard2, Markus Graefen3, Francesco Montorsi4,
Pierre I. Karakiewicz1
Roswell Park Cancer Institute, Buffalo, NY, United
States; 2University of Buffalo, Buffalo, NY, United
States; 3University of Michigan, Ann Arbor, MI, United
States; 4Vanderbilt University School of Medicine,
Nashville, TN, United States
1
P118. Optimization of the Nanolantern™
Assay for Rapid Detection of Common
Urinary Tract Pathogens
University of Rochester, Rochester, NY, United States
4:51 p.m.
5 p.m.
4 – 5 p.m.
4 p.m.
Discussion
Adjourn
Moderated Poster Session VIII:
Kidney Cancer
Moderators: John M. Fitzpatrick and
Wassim Kassouf
P119. Fast Track Open Partial
Nephrectomy: A Feasibility Study
Bilal Chughtai1, Stuart Rosenberg2, Daniel Finn3,
Michael Perrotti3
Albany Medical Center, Albany, NY, United States; 2St
Peters Hospital, Albany, NY, United States; 3St Peter's
Hospital, Albany, NY, United States
1
4:03 p.m.
28
P120. Role of Biopsy in the
Management of Small Renal Masses
Bilal Chughtai, Ronald P. Kaufman Jr., Hugh A.
G. Fisher, Gary Sisken, Badar Mian
Albany Medical Center, Albany, NY, United States
P124. Tumor Size is a Determinant of
the Rate of Synchronous Metastases in
Patients with T1 Stage Renal Cell
Carcinoma
Willie Underwood, III1, Heather Orom2, Brady
West3, Jay Fowkes4
Jennifer G. Rothschild, Christopher M.
Strohsahl, Ganesh S. Palapattu, Benjamin L.
Miller
P123. Preliminary Report of a Pilot Study
of Neoadjuvant Sunitinib for Clinical M0
Renal Cell Carcinoma
Nicholas Hellenthal, Joel Gajewski, Marcus
Sikorski, Hyung Kim
Treatment Choice
4:48 p.m.
P122. Factors Predicting Renal
Impairment on Long-Term Follow-Up,
Following Partial Nephrectomy:
Mcgill 10 Years Experience
Ahmed F. Kotb, Tamer H. Abou Youssif, Murilo
A. Luz, Armen Aprikian, Wassim Kassouf, Fadi
Brimo, Simon Tanguay
Andrew R. McCullough1, Herbert Lepor1, Run
Wang2, Kristopher R. Wagner3, Wayne J. G.
Hellstrom4, Jason D. Engel5
1
P121. The Impact on Renal Function
After Partial vs. Radical Nephrectomy
for Renal Cell Carcinoma: A Systematic
Review
University of Montréal, Montréal, QC, Canada;
Rennes University Hospital, Rennes, France;
3Prostate Cancer Center Hamburg-Eppendorf,
Hamburg, Germany; 4Vita-Salute University, Milan, Italy
1
2
4:18 p.m.
P125. Conditional Survival Predictions
After Nephrectomy for Renal Cell
Carcinoma
Claudio Jeldres1, Nazareno Suardi1, Umberto
Capitanio1, Hendrik Isbarn1, Paul Perrotte1,
Vincenzo Ficarra2, Richard Zigeuner3, Jacques
Tostain4, Arnaud Mejean5, Luca Cindolo6, Allan J.
Pantuck7, Arie S. Belldegrun7, Laurent Zini8,
Alexandre de la Taille9, Denis Chautard10,
Jean-Luc Descotes11, Shahrokh F. Shariat1,
Antoine Valeri12, Peter F. A. Mulders13, Herve
Lang14, Eric Lechevallier15, Jean-Jacques Patard16,
Pierre I. Karakiewicz1
1
University of Montréal, Montréal, QC, Canada; 2University of Padua, Padua, Italy; 3Medical University of
Graz, Graz, Austria; 4University Hospital of Saint-Etienne, Saint-Etienne, France; 5Necker Medical School,
Paris, France; 6G. Rummo Hospital, Benevento, Italy;
7
David Geffen School of Medicine, Los Angeles, CA,
United States; 8University of Lille, Lille, France; 9Henri
Mondor University Hospital, Creteil, France; 10University of Angers, Angers, France; 11Medical University of
Northeastern Section of the AUA — 2009 Annual Meeting
Grenoble, Grenoble, France; 12Brest University Medical
School, Brest, France; 13Radboud University, Nijmegen,
Netherlands; 14University of Toulouse, Toulouse,
France; 15Marseille University, Marseille, France;
16
Rennes University Hospital, Rennes, France
4:21 p.m.
P126. Prognostic Significance of
1University of Montréal, Montréal, QC, Canada; 2Lille
University Hospital, Lille, France; 3Vita-Salute San raffaele, Milan, Italy; 4Vita-Salute San Raffaele, Milan,
Italy; 5Vita Salute San Raffaele, Milan, Italy; 6Vita-Salute
San Raffaele, Montréal, Italy
4:36 p.m.
Nephron-Sparing Surgery has the Same
Cancer Control than Radical Nephrectomy: A Population-Based Assessment
Giovanni Lughezzani1, Umberto Capitanio2,
Claudio Jeldres1, Hendrik Isbarn1, Shahrokh F.
Shariat1, Philippe Arjane1, Hugues Widmer1, Paul
Perrotte1, Francesco Montorsi2, Pierre I.
Karakiewicz1
Salima Ismail1, Claudio Jeldres1, Maxime
Crepel1, Hendrik Isbarn1, Giovanni Lughezzani1,
Maxine Sun1, Daniel Liberman1, Shahrokh F.
Shariat1, Daniel Pharand1, Phillippe Arjane1,
Francesco Montorsi2, Paul Perrotte1, Pierre I.
Karakiewicz1
University of Montréal, Montréal, QC, Canada;
Vita-Salute University, Milan, Italy
1
2
4:24 p.m.
University of Montréal, Montréal, QC, Canada;
Vita-Salute San Raffaele, Milan, Italy
1
P127. Pushing the Limits of Partial
Nephrectomy: Time to Pause?
2
4:39 p.m.
Claudio Jeldres1, Maxime Crepel1, Umberto
Capitanio1, Paul Perrotte1, Hendrik Isbarn1,
Giovanni Lughezzani1, Maxine Sun1, Shahrokh
F. Shariat1, Hugues Widmer1, Markus Graefen2,
Francesco Montorsi3, Pierre I. Karakiewicz1
University of Montréal, Montréal, QC, Canada;
Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany; 3Vita-Salute San Raffaele, Milan, Italy
2
P128. A Population-Based Analysis of
the Rate of Cytoreductive Nephrectomy
for Metastatic Renal Cell Carcinoma in
the United States
Daniel Liberman1, Claudio Jeldres1, Sara
Baillargeon-Gagne1, Hendrik Isbarn1, Umberto
Capitanio1, Shahrokh F. Shariat1, Maxine Sun1,
Giovanni Lughezzani1, Paul Perrotte1, Francesco
Montorsi2, Markus Graefen3, Pierre I.
Karakiewicz1
University of Montréal, Montréal, QC, Canada;
Rennes University Hospital, Rennes, France;
3Vita-Salute San Raffaele, Milan, Italy; 4Martiniclinic,
Prostate Cancer Center Hamburg-Eppendorf,
Hamburg, Germany
1
2
4:42 p.m.
1University of Montréal, Montréal, QC, Canada; 2VitaSalute San Raffaele, Milan, Italy; 3Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany
4:30 p.m.
Radoslav Krouchev1, Hendrik Isbarn1, JeanJacques Patard2, Claudio Jeldres1, Maxine Sun1,
Giovanni Lughezzani1, Paul Perrotte1, Pierre I.
Karakiewicz1
University of Montréal, Montréal, QC, Canada; 2Martiniclinic, Prostate Cancer Hamburg-Eppendorf, Hamburg, Germany; 3Vita-Salute San Raffaele, Milan, Italy;
4Rennes University Hospital, Rennes, France
1
University of Montréal, Montréal, QC, Canada;
Rennes University Hospital, Rennes, France
1
2
P130. Can Renal Mass Biopsy
Assessment of Tumor Grade Be Safely
Substituted with a Predictive Model?
Daniel Liberman1, Claudio Jeldres1, Maxine
Sun1, Alexandre de la Taille2, Jacques Tostain2,
Antoine Valeri2, Luca Cindolo3, Vincenzo Ficarra4,
Walter Artibani5, Richard Zigeuner2, Arnaud
Mejean2, Jean Luc Descotes2, Eric Lechevallier2,
Peter F. Mulders2, Francesco Montorsi6, Paul
Perrotte1, Jean-Jacques Patard2, Pierre I.
Karakiewicz1
P133. Nephron-Sparing Surgery Is
Equally Effective to Radical
Nephrectomy for T1bN0M0 Renal
Cell Carcinoma: A Population-Based
Assessment.
Nawar Hanna1, Maxime Crepel1, Claudio
Jeldres1, Paul Perrotte1, Umberto Capitanio1,
Hendrik Isbarn1, Shahrokh F. Shariat1, Giovanni
Lughezzani1, Maxine Sun1, Philippe Arjane1,
Hugues Widmer1, Markus Graefen2, Francesco
Montorsi3, Jean-Jacques Patard4, Pierre I.
Karakiewicz1
P129. Tumor Necrosis Is Not an
Informative Marker of Cancer-Specific
Mortality in Patients with all Stages of
Renal Cell Carcinoma
4:33 p.m.
P132. A Comparative Population-Based
Analysis of the Rate of Partial vs. Radical
Nephrectomy for Clinical Localized
Renal Cell Carcinoma
Salima Ismail1, Sara Baillargeon-Gagne1, Claudio
Jeldres1, Giovanni Lughezzani1, Hendrik Isbarn1,
Umberto Capitanio1, Shahrokh F. Shariat1,
Maxime Crepel1, Maxine Sun1, Hugues Widmer1,
Philippe Arjane1, Jean-Jacques Patard2, Paul
Perrotte1, Francesco Montorsi3, Markus Graefen4,
Pierre I. Karakiewicz1
1
4:27 p.m.
P131. For T1an0m0 Renal Cell Carcinoma,
Lymph Node Invasion in Patients with
Metastatic Renal Cell Carcinoma: A
Population-Based Perspective
4:45 p.m.
P134. Simplified Fuhrman Grade Is
Equally Informative to the Conventional
Fuhrman Grade: A Population-Based
Analysis
Maxine Sun1, Giovanni Lughezzani1, Claudio
Jeldres1, Hendrik Isbarn1, Philippe Arjane1,
Hugues Widmer1, Daniel Pharand1, Shahrokh F.
Shariat1, Francesco Montorsi2, Paul Perrotte1,
Pierre I. Karakiewicz1
University of Montréal, Montréal, QC, Canada; 2VitaSalute San Raffaele, Milan, Italy
1
29
4:48 p.m.
Discussion
5 p.m.
Adjourn
5:30 – 6:30 p.m. Residents’ Reception
7 – 10 p.m.
Fun Night at Cirque Éloize
N U RS I NG PROG RAM
FRIDAY, OCTOBER 9, 2009
7:30 a.m. – 4 p.m.
Fairmont Queen Elizabeth
SATURDAY, OCTOBER 10, 2009
6:30 – 7:30 a.m.
Industry-Sponsored Breakfast
Symposium
Saint Laurent/Gatineau
7:30 – 8 a.m.
8 – 8:15 a.m.
Revisiting Testosterone Levels Achieved
with Androgen Ablation: What is Optimum Suppression?
Judd Moul, Duke University Medical Center,
Durham, North Carolina, United States
President, Northeastern Section of the AUA
Frances Stewart, RN
Past President, Urology Nurses of Canada
8:15 – 9 a.m.
Annual Business Meeting
Residents’ Breakfast
How to Select a Urology
Fellowship Program
8:30 – 8:45 a.m.
8:45 – 9:30 a.m.
Shahrokh Shariat, Dallas, Texas, United States
Best-Of-Poster Session
Presented by moderators of previous day’s
poster sessions
Slotkin Lecture
J. Curtis Nickel, MD
Kingston General Hospital, Kingston, ON, Canada
9 – 9:45 a.m.
University of Western Ontario, London, ON, Canada
9:45 – 10:15 a.m. Break in Exhibit Hall
10:15 – 11 a.m.
Screening for Prostate Cancer with PSA:
Significance of Recent Screening Studies
Edward M. Messing, MD
University of Rochester, Rochester, NY, United States
11 a.m. – Noon
Consultant Pediatric Urologist, London, England
Queensway Carllton Hospital, Ottawa, ON, Canada
Moderator: Pierre Karakiewicz
Welcome and Introduction
Androgen Deprivation Therapy
Edward M. Messing
Moderator: TBD
Noon – 1:30 p.m. Lunch in Exhibit Hall
1:30 – 2:30 p.m. Women's Incontinence
Martine Jolivet-Trembley, MD
University of Rochester, Rochester, New York,
United States
Panelists: Alexandre R. Zlotta and
D. Andrew Loblaw
10:15 – 10:45 a.m. Break
10:45 a.m.
Plenary Session VII
Moderator: Anne-Marie Houle
10:45 a.m.
10:50 a.m.
Welcome and Introduction
Urinary Obstruction from the Cradle to
the Grave
Sir Phillip Ransley
Consultant Pediatric Urologist, London, England
11:20 a.m.
Stress Urinary Incontinence and
Unstable Bladder
Panelists: Jerzy Gajewski and Sender Hershorn
Moderators: Luc Valiquett, Serge Carrier and
Martine Jolivet-Tremblay
Innovative Nursing Roles in a New
Regional Cancer Surgery Program
Susan Freed, RN, BScN
9:30 – 10:15 a.m. Plenary Session VI
9:30 a.m.
9:35 a.m.
The Role of Nursing in Management of
the Couple with ED/Infertility
Gerald Brock, MD, FRCSC
Sun, Light and Shadows
Moderator: Anne-Marie Houle
Sir Phillip G. Ransley
Education Session
Prostatitis: A Phoenix Rising from the
Ashes
Sponsored by Ferring Pharmaceuticals
7:30 – 8:30 a.m.
7:30 – 8:30 a.m.
Breakfast
Welcome
Anne-Marie Houle, MD
University of Montréal, Montréal, QC, Canada
2:30 – 3:15 p.m.
Children’s Incontinence and
Biofeedback Program
Catherine Daniels, RN, MS, ACNP
Hospital for Sick Children, Toronto, ON, Canada
3:15 – 4 p.m.
TURP Syndrome Revisited
Carol-Anne Lee-Desmarais, RN, BN
McGill University Health, Royal Victoria Hospital,
Montréal, QC, Canada
Continuing Nursing Education Credits
This activity has been submitted to the Society of Urologic
Nurses and Associates (SUNA) for approval to award 5.75 contact hours. SUNA is accredited as an approver of continuing
nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
University of Montréal, Montréal, Quebec, Canada
30
Noon
12:30 p.m.
12:30 – 4 p.m.
6:30 – 10 p.m.
Adjourn
Tennis Tournament
Historic Tour of Old Montréal
President’s Reception & Banquet
Northeastern Section of the AUA — 2009 Annual Meeting
Social Program
N ETWORKI NG RECEPTION
Complimentary
Thursday, October 8, 2009
Time: 7 – 9 p.m.
Location: Fairmont Queen Elizabeth Hotel
Drop the gloves and shake hands
with your colleagues at the
Opening Day Networking
Reception. Help celebrate the 100th anniversary of the
Montréal Canadiens hockey team. Food, beverages and
entertainment will be provided. Come, network
with your colleagues and friends and enjoy!
TOU RS
The following tours have been reserved for guests on
Friday, October 9 and Saturday, October 10, 2009. Each
tour group will meet at the Mansfield entrance in the
lobby of the Fairmont Queen Elizabeth Hotel prior to
departure. Guests are encouraged to pre-register for
tours when they pre-register for the conference, as
spots will fill quickly. On-site tour registration will take
place at the hotel on Thursday, October 8 between 7
a.m. and 5 p.m. and will be available on a first-come,
first-served basis. Payments can be made on site at the
hotel for any tours that have not been pre-registered or
pre-paid. Please note that if minimum numbers are not
met, tours will be cancelled.
Friday, October 9, 2009
Tour Option:
Tour Time:
Cost:
Botanical Garden, Insectarium & Biodôme
9 a.m. – 3 p.m.
$57
[Includes taxi transportation; professional tour guide; entrance admission to the Botanical Gardens, Insectarium
and Biodôme; guide and driver gratuities; and all applicable
taxes.]
Travel by reserved cab to spend a fabulous day
exploring Montréal’s flora and fauna! The Montréal
Botanical Garden (Le Jardin Botanique) houses a
collection of 22,000 plant species and cultivars, 10
exhibition greenhouses, 30 thematic gardens, as well
as teams of researchers and informative staff. The
Montréal Botanical Garden ranks as one of the world’s
largest and most spectacular botanical gardens. A
magical exhibition of lanterns will be on display in the
Chinese Garden while we are there.
We will also explore the ever-popular Montréal
Insectarium— located adjacent to the Botanical
Garden—which has welcomed hundreds of thousands
of visitors intrigued by these misunderstood creatures,
so often wrongly feared and despised. The goal of the
Insectarium is to awaken visitors to the wonders of the
insect world, and to explain how insects play an essential part in ensuring the Earth’s ecological balance.
Following the Insectarium tour, the group will be
escorted across the street and through the site of the
1976 Olympic Games to what was originally designed
as the cycling track. An oasis in the heart of the city,
the facility has been transformed into the Montréal
Biodôme, which recreates four distinct climates that
are home to the native flora and fauna of the region,
truly some of the most beautiful ecosystems of the
world: the lush and humid Tropical Forest, the Laurentian Forest, the St. Lawrence Marine Ecosystem, and the
Polar Worlds of the Arctic and Antarctic.
Once the tour of the Biodôme has come to an end,
you will take reserved taxi cabs back downtown where
you’ll find a variety of restaurants and an excellent
opportunity to explore the downtown core with an
experienced guide. Following lunch on your own, you
will be escorted back to the hotel.
Saturday, October 10, 2009
Tour Option:
Tour Time:
Cost:
Old Montréal Historical Tour
12:30 – 4 p.m.
$63
[Includes transportation, professional tour guide, Pointe-àCallière Museum entrance fees, guide and driver gratuities,
and all applicable taxes.]
Montreal City Hall
31
From the place where the city was founded in 1642
at Pointe-à-Callière, to the lively destination of Place
Jacques Cartier, you’ll explore the rich history of this
spectacular metropolis. With simplicity and humor, your
guide will lead your group through a maze of cobblestone streets and historic buildings for a unique look at
Old Montréal.
The coach will drop off the guests at Pointe-àCallière for a tour of the Museum, and from there a
guide will escort the group through Old Montréal—from
Place d’Armes and Place Royal, to the Court houses,
Château Ramezay and Bonsecours Market—offering a
charming look at this city’s rich history.
The Lachine Canal path, with more than one million
visitors each year, is the most popular path in Canada.
It extends more than 11 km (7 miles) and is a national
historic site. Its banks, while welcoming to cyclists,
runners and strollers, are also considered the cradle of
industrialization in Canada. For breathtaking scenery
with a historic touch, this is the place to be.
You can pre-register for this event when you preregister for the conference on the Web site, or you can
register on site. Prizes will be given to the top three
male and female runners.
NS-AUA 5k
Run/Walk for Residents Courrir/Marcher pour les résidents
Montréal
TEN N I S TOU RNAM ENT
Saturday, October 10, 2009
Friday, October 9 2009, 6:30 a.m.
Vendredi, 9 Octobre 2009, 6:30
Time: 12:30 – 3:30 p.m.
Location: Nuns’ Island Indoor Tennis Club
Cost:
$30 [Includes tennis balls, hand towels, water, sports
drinks, sodas, fruit and granola bars.]
5K RU N FOR RES I DENTS
For Runners and Walkers
Friday, October 9, 2009
Time: 6:30 – 8 a.m. (Race begins at 7 a.m.)
Location: Lachine Canal
Cost:
$15
[Includes run t-shirt, water, fresh fruit and granola bars.]
Note: All proceeds go toward the Section’s Foundation
in support of educational and research grants for
residents.
Enjoy our tennis tournament at the Nuns’ Island Indoor Tennis Club. With 20 hard courts and under the
directon of Conrad Pineau, Nun’s Island is the leader in
Canadian tennis. Without a doubt, their school of tennis is the reason for the club’s success. You can preregister for this event when you register for the
conference or you can register on site when you arrive.
S POU S E LOU NG E
Location: Suite 1742 – John Lennon Suite
32
Come run (or walk) for residents! Or, if you prefer, be a
sleepwalker —stay in bed and contribute $15 to the
Section’s Foundation in support of educational and research grants for residents.
The air is clean and crisp and the sun rises as you arrive to register for the race. Colorful rays glisten along
the regal Lachine Canal as you take in the scenic area.
Trees lining the canal from the Old Port to Lac SaintLouis sprinkle their leaves along the path in vivid fall
tones. With your running shoes laced and a water bottle in hand, you’re ready to go!
The celebrated singer-songwriter John Lennon and his
wife Yoko Ono choose the suite 1742 at the Fairmont
The Queen Elizabeth hotel for their “Bed-in.” This historical event for peace began on May 26, 1969. The
highlight of this significant event was John Lennon’s
composition of the song ‘’Give Peace a Chance’’.
Hours of Availability:
Thursday, October 8: 7 – 9 a.m.
Friday, October 9: 7 – 9 a.m.
Saturday, October 10: 7 – 9 a.m.
Northeastern Section of the AUA — 2009 Annual Meeting
&
Reception at 6:30 p.m.,
Banquet, Program and Awards at 7 p.m.
Attire: Semi-formal attire
Cost: If you have registered for the NS-AUA’s 2009 Annual Meeting,
you will receive one complimentary ticket (Residents receive
two tickets). Additional tickets are $75 and can be purchased
at the Registration Desk.
Join us for a reception and dinner with keynote speaker, Richard
Béliveau, PhD. Dr. Béliveau obtained his PhD from Université Laval and
went on to complete his post-doctoral training at Cornell University
in New York. He holds the Chair for Cancer Prevention and Treatment
at Université du Québec à Montréal and has been a professor in its
Biochemistry Department since 1984. He is the author of several books
on foods that fight cancer. He is also an associate professor in the
Department of Surgery at Université de Montréal.
Dr. Béliveau has been Director of the Molecular Medicine
Laboratory at Sainte-Justine Hospital since 1996. He is also a member
of the Department of Hemato-Oncology at Sainte-Justine, of the
Neurosurgery-Oncology division at the Centre Hospitalier de
L’Université de Montréal (CHUM) and of the Montréal Centre for
Experimental Therapeutics in Cancer (MCETC) at the SMBD-Jewish
General Hospital.
The fight against cancer is at the heart of Dr. Béliveau’s scientific
and humanitarian efforrts. His team, comprised of 35 people, works
on three main projects: brain tumors and the blood-brain barrier,
tumor vascularization (angiogenesis) and the prevention of cancer
through nutrition (nutraceuticals).
Dr. Béliveau and the hotel chef have designed the menu for this
event to coincide with his cancer-fighting research in the area of
nutrition.
Quick Guide to Montréal
Meeting and Accommodations Location:
Fairmont The Queen Elizabeth Hotel
900 René–Lévesque Boulevard West
Montréal, Québec, Canada H3B 4A5
Phone: 1-514-861-3511 or 1-800-441-1414
Fax: 1-514-954-2256
Hotel Web site: www.fairmont.com/queenelizabeth
TOU RI ST I N FORMATION:
Visit www.tourisme-montreal.org to learn more about
the host city for this year’s Annual Meeting.
Highlights:
I Old
Montréal: The city’s enchanting historic quarter,
with cafés, cobblestones and gourmet restaurants, a
mix of Old World charm and modern flair.
I Sainte-Catherine Street: Canada’s shopping mecca
with 1,200 stores over a nine-mile (15- km) stretch of
downtown Montréal.
I The Underground Pedestrian Network: Boasting
more than 20 miles (33 km) of weather-protected
passageways, this unique pedestrian walk connects
you to the subway, shops, restaurants, movie theatres and more.
I Get your culture fix at the Museum of Fine Arts,
Musée D’Art Contemporain, Canadian Centre for Architecture, Redpath Museum and McCord Museum
of Canadian History.
I Outdoor activities include more than 1,000 parks,
water sports and cruises along the majestic St.
Lawrence River, plus bike paths galore.
I As North America’s gastronomic capital, Montréal
features over 6,500 restaurants representing 80 different cultures.
WEATH ER:
The weather in Montréal varies depending on the season, so you are encouraged to check the forecast before packing. The average high temperature in October
is 55° Fahrenheit (13°C).The average low temperature
is 39° Fahrenheit (4°C).
AI RPORT:
Pierre Elliott Trudeau International Airport
Web site: www.admtl.com
The main Canadian airport east of the Great Lakes,
Montréal-Trudeau’s world-class air terminal is designed
to provide you with the most efficient, comfortable and
safe airport experience possible. Every year, about 40
air carriers transport more than 11 million passengers
via Montréal-Trudeau. There are direct flights to and
from approximately 120 regular and seasonal destinations in Canada, the United States and internationally.
TRAN S PORTATION:
L’Aérobus: Service provides an efficient connection by
motor bus between Montréal-Trudeau airport and
downtown Montréal.
Cost:
$15 Canadian Dollars (CAD) one-way for an adult,
$25 CAD roundtrip
Hours: Departures are 24 hours a day.
Detailed schedule is available at
www.autobus.qc.ca/anglais/horaire_an.html.
Travel time is 30-45 minutes, depending on traffic.
Reservations: Not required. Tickets can be purchased
at the Montréal Central Bus Station and at MontréalTrudeau (arrivals level).
Taxis: Taxis and limousines are available at the airport
at the arrivals level near the central exit located in front
of the cloakroom. The fixed fare for Downtown is $38
CAD for a taxi or $49.50 CAD for a limousine. Visa,
MasterCard and American Express credit cards are accepted. Some drivers accept U.S. currency but provincial regulations require customers to pay in Canadian
currency.
RENTAL CARS:
Avis is offering special discounted rates to all meeting
attendees. Reservations can be made by calling:
1-800-331-1600
Hearing Impaired/TDD 1-800-331-2323
Spanish Translation 1-800-874-3556
Use the AUA Discount code: J907607
HOTEL I N FORMATION:
Fairmont The Queen Elizabeth Hotel
Location: Located in the heart of downtown Montréal,
walking distance to all major attractions, the Fairmont
is a landmark, superior class hotel connected to the
world famous underground city and subway. It is situated directly over Central Station.
Room Rates: $179 CAD Single/Double per night, $249
CAD Triple
Reservation Cut-off Date: August 28, 2009
Important Note: Rooms are available on a first-come
first-served basis. The NS-AUA is holding a block of
rooms at the hotel listed above. It is advised that you
book reservations at your earliest possible convenience. The room block may sell out prior to the cut-off
date for reservations. Should this occur the NS-AUA is
unable to guarantee additional reservations at this
hotel.
35
Check-in: 4 p.m.
Check-out: Noon
Credit Cards Accepted: Amex, Visa, Diners, Discover
and Master Card
Parking: Valet parking is available for $26 CAD/night
with unlimited in/out access.
Fitness Center: The Health Club is complimentary to
all guests and is accessible from 6 a.m. to 10 p.m. daily.
It will invigorate you with its indoor pool, steam room,
whirlpool, state-of-the-art “Keiser” equipment and a
variety of cardiovascular machines.
Room Service: Available 24 hours, 7 days a week.
Hotel Restaurants:
Guestroom Common Amenities
(all rooms offer the following amenities):
I coffee maker including complimentary coffee/tea
I mini-bar
I iron and ironing board
I hairdryer
I color television with remote control and cable with
in-room pay-per-view movies
I alarm clock-radio
I telephone with voicemail
I individual climate control
Guestroom Amenities on Request
(the following amenities may be available – please indicate the request in your reservation or ask one of the
reservation agents):
I connecting rooms
I cribs
I mini-refrigerator (extra $20 CAD)
I sofa bed
I special needs amenities: alarm clock-radio (vibrating); amplifier for partially hearing-impaired guests;
bathroom with grab-bar and adapted height for the
toilet, lower sink; door knock sensor; flashing light
for call/smoke detector alert; telecaption for TV and
TTY
Business Center: XEROX, a full service business center, is located on the lower lobby level (Level S1) and
can assist you with all of your business needs. Services
include work stations with high-speed Internet access,
color and black-and-white printing/copying, fax services and scanning. It is open Monday through Friday, 8
a.m. to 5:30 p.m.
Internet Service: Wired Internet access is available in
every guest room for $13.95 CAD plus taxes for 24
hours. However, if you are a member of the Fairmont’s
President Club prior to your arrival, you can benefit
from free Internet access in your guest room. See
below for additional details.
36
I Le
Montréalais: Bistro style, casual restaurant serving breakfast, lunch, dinner and Sunday brunch.
Open 7 days a week, 6:30 a.m. to 11 p.m.
I Beaver Club: French cuisine, jacket required, rated
one of Canada’s top 10 restaurants – AAA 4 Diamond award-winner
Lunch – Monday through Friday, Noon to 3 p.m.
Dinner – Tuesday through Saturday, 6 to 11 p.m.
I Les Voyageurs: Bar/lounge serving lunch, dinner and
light snacks
Monday through Friday, Noon – 1 a.m.
Saturday and Sunday, 4 p.m. – 1 a.m.
I Tea Lounge: Open Monday through Sunday, 2:30 –
6 p.m.
Gift Shops: Gift shops are located on the lobby level of
the hotel. Also, the hotel is connected to Place Ville
Marie, an underground shopping area with more than
60 stores.
Babysitting: Bonded babysitters are available, with a
four-hour minimum notice required. The price for one
or two children is $20 CAD/hour with a three-hour
minimum charge. Additional costs apply for three or
more children. Reservations can be made through the
Concierge Desk.
Pets: Pets less than 20 pounds are permitted in the
hotel. A charge of $25 CAD/day will apply. The animal
must be kept in a kennel at all times and must not be
left unattended in the room. Seeing-eye dogs are always welcome and are exempt of charges and restrictions.
Fairmont President’s Club: Fairmont Hotels & Resorts’ exclusive guest recognition program, Fairmont
President’s Club, offers special benefits and privileges
designed to reflect your individual travel preferences.
Membership is complimentary and your experience begins the moment you arrive at the Fairmont with express check-in. You will also receive complimentary
high-speed Internet access in your guest room, free
local calls, complimentary daily newspaper and more.
Please visit www.fairmont.com/fpc to enroll, and remember that you must enroll prior to your arrival to
benefit from the privileges.
Northeastern Section of the AUA — 2009 Annual Meeting
Exhibitor Listing (Alphabetical)
ALLERGAN, INC.
21
2525 Dupont Drive
BOSTON SCIENTIFIC
Irvine, CA 92612 USA
Marlboro, MA 01752 USA
Phone: 714-246-4500
Phone: 508-650-8000
Web site: www.Allergan.com
Web site: www.bostonscientific.com
Allergan, Inc. is a multi-specialty healthcare company. We are
pleased to offer a number of leading products, including: SANCTURA XR™ (trospium chloride extended release capsules), BOTOX®
(Botulinum Toxin Type A), RESTASIS® (cyclosporine ophthalmic
emulsion) 0.05%, LUMIGAN® (bimatoprost ophthalmic solution)
0.03%, and BOTOX® Cosmetic (Botulinum Toxin Type A).
AMERICAN MEDICAL SYSTEMS
5
100 Boston Scientific Way
66
Boston Scientific is a leading developer of less invasive technologies.
Our products include devices for the treatment of kidney stones,
BPH, female urinary incontinence and pelvic floor reconstruction.
Please visit us to learn about our newest technologies.
CALMOSEPTINE, INC.
69
75 York Street, Suite 1508
Kitchener, Ontario N2G 1T5 CANADA
10700 Bren Road West
Phone: 519-741-9295
Minnetonka, MN 55343 USA
Web site: www.calmoseptineointment.com
Phone: 952-930-6000
Web site: www.AmericanMedicalSystems.com
American Medical Systems is a world leader in medical devices and
procedures that treat four major diseases: incontinence, prolapse,
erectile dysfunction and benign prostate hyperplasia (BPH). Any one
of these conditions can profoundly diminish a patient’s quality of life
and significantly impact relationships. Our products provide a cure or
reduce the incapacitating effects of these diseases, often through
minimally invasive surgery.
ASTELLAS PHARMA CANADA, INC.
71
Calmoseptine Inc. promotes Calmoseptine® Ointment for the prevention and treatment of skin irritations from moisture such as urinary
and fecal incontinence. It is also effective for irritations from perspiration, wound drainage, fecal and vaginal fistulas and feeding tube
site leakage. Calmoseptine® Ointment temporarily relieves discomfort
and itching. Free samples at our booth!
COLOPLAST CORP.
73
1601 West River Road North
Minneapolis, MN 55411 USA
Phone: 612-337-7800
675 Cochrane Drive, Suite 500, West Tower
Web site: www.straighttalk.com
Markham, Ontario L3R 0B8 CANADA
Phone: 905-470-7990
Web site: www.astellas.com/ca/en/
Astellas Pharma US, and Astellas Pharma Canada are affiliates of
Tokyo-based Astellas Pharma Inc., a pharmaceutical company dedicated to “Changing tomorrow” by improving the health of people
around the world through innovative and reliable pharmaceutical
products. For more information please visit our Web sites at
www.astellas.com/us, and www.astellas.com/ca.
Coloplast is a leading global manufacturer and marketer of innovative medical devices for the management and treatment of urological
disorders to include incontinence, retention and ED. Stop by booth
73 to learn about our new Virtue male sling, the alternative approach
to treating stress urinary incontinence.
COOK MEDICAL INCORPORATED
14
P.O. Box 489
Bloomington, IN 47401 USA
AUXILIUM PHARMACEUTICALS, INC.
78
Phone: 800-468-1379
40 Valley Stream Parkway
Phone: 812-339-2235
Malvern, PA 19355 USA
Phone: 812-339-3704
Phone: 484-321-2136
Web site: www.cookmedical.com
Web site: www.auxilium.com
Auxilium engages in the global development, marketing, and sales of
ethical pharmaceutical products that maintain functionality in an
aging male population. Auxilium’s lead product, Testim® 1% (testosterone gel) CIII, is indicated for the treatment of hypogonadism. Auxilium's continued focus is in developing/acquiring novel molecules
with viability in the urological field.
Cook Medical was one of the first companies to help popularize interventional medicine, pioneering many of the devices now commonly used worldwide to perform minimally invasive medical
procedures. Today, the company integrates minimally invasive medical device design, biopharma, gene and cell therapy, and biotech to
enhance patient safety and improve clinical outcomes in the fields of
aortic intervention; interventional cardiology; critical care medicine;
gastroenterology; radiology, peripheral vascular, bone access and oncology; surgery and soft tissue repair; urology; and assisted reproductive technology, gynecology and high-risk obstetrics. Founded in
1963 and operated as a family-held private corporation, Cook is a
past winner of the prestigious Medical Device Manufacturer of the
Year Award from Medical Device & Diagnostic Industry magazine.
37
DENDREON CORPORATION
18
FERRING PHARMACEUTICALS
3005 First Avenue
4 Gatehall Drive, 3rd Floor
Seattle, WA 98121 USA
Parsippany, NJ 07054 USA
Phone: 206-256-4545
Phone: 973-796-1600
Web site: www.dendreon.com
Phone: 1-888-FERRING (337-7464)
Dendreon Corporation is a biotechnology company whose mission is
to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics that harness the
immune system to fight cancer.
ELI LILLY CANADA, INC.
25
60
3650 Danforth Avenue
Scarborough, Ontario M1N 2E8 CANADA
Web site: www.ferringusa.com
Web site: www.firmagon.com
Ferring Pharmaceuticals announces new FIRMAGON® (degarelix for
injection), the trade name for degarelix. Ferring previously introduced
Prosed® DS. Ferring Pharmaceuticals specializes in six therapeutic
areas: urology, infertility, obstetrics, gastroenterology, endocrinology,
and osteoarthritis.
HEALTHTRONICS, INC.
Phone: 416-693-3790
36
9825 Spectrum Drive, Building 3
Web site: www.lilly.ca
Austin, TX 78717 USA
Eli Lilly is a leading, innovation-driven pharmaceutical corporation
committed to providing answers that matter through medicines and
information, for some of the world's most urgent medical needs.
Lilly, une société pharmaceutique de pointe axée sur l’innovation est
résolue à apporter des réponses qui comptent, sous forme de
médicaments et d'informations, pour certains des impératifs médicaux les plus urgents dans le monde.
ELSEVIER CANADA
8
905 King Street West, 4th Floor
Phone: 512-328-2892
Web site: www.healthtronics.com
HealthTronics® is the leading provider of urology products and services offering the latest technology in prostate therapies for BPH and
cancer, lithotripsy and uropathology services. Through ClariPath Laboratories®, our anatomic pathology laboratory, we offer multiple business solution models and the most advanced technology available
ensuring accurate results and rapid turnaround times.
INTUITIVE SURGICAL, INC.
Toronto, Ontario M6K 3G9 CANADA
1266 Kifer Road, Building 101
Phone: 416-644-7090
Sunnyvale, CA 94086 USA
Web site: www.elsevier.com
Phone: 408-523-2100
Elsevier Canada is a team of leading publishers including Saunders,
Mosby, Churchill Livingstone, Butterworth-Heinemann, Hanley & Belfus, MDConsult and FIRSTConsult dedicated to meeting the information needs of health science professionals. We publish high-quality
textbooks, references, periodicals, and electronic products for medicine, nursing, dentistry, veterinary medicine, and health professions.
ENDO PHARMACEUTICALS
4
100 Endo Boulevard
3
Web site: www.intuitivesurgical.com
Intuitive Surgical, Inc. is shaping the future of urologic minimally invasive surgery. The da Vinci® Prostatectomy represents the number
one treatment for prostate cancer in the United States today, leveraging the da Vinci® Surgical System’s state-of-the-art technology.
Visit www.daVinciProstatectomy.com and www.daVinciSurgery.com
today.
Chadd's Ford, PA 19317 USA
KARL STORZ ENDOSCOPYAMERICA, INC.
Phone: 610-558-9800
2151 East Grand Avenue
Web site: www.endo.com
El Segundo, CA 90245
Endo Pharmaceuticals is a specialty pharmaceutical company with a
broad portfolio of branded and generic prescription products focused on providing relief from pain. Endo is dedicated to improving
the lives of patients through identifying, developing, and marketing
innovative and differentiated products in pain management and related therapeutic areas, including urology and endocrinology.
Web site: www.karlstorz.com
KARL STORZ Endoscopy-America, Inc., a leader in endoscopic
equipment and instruments, markets products that emphasize
visionary design and precision craftsmanship. Our urology line
includes the revolutionary flexible video cystoscopes, combining
the versatility of flexible endoscopes with advanced distal chip
technology. We also offer the industry’s only STERRAD®
NX™/100NX™-compatible flexible fiberscopes.
38
Northeastern Section of the AUA — 2009 Annual Meeting
19
KARL STORZ LITHOTRIPSY-AMERICA, INC 19
PD LABS
1000 Cobb Place Boulevard
19230 Stone Oak Parkway #200
22
Building 400 Suite 450
San Antonio, TX 78258 USA
Kennesaw, GA 30144
Phone: 210-494-1678
Web site: www.karlstorz.com
Web site: www.pdlabs.com
The Storz MODULITH® SLX-F2 is a one-of-a-kind lithotripter as well
as a diagnostic and therapeutic workstation. Equipped with patented,
electromagnetic shock wave technology, offering selectable focus as
well as in-line ultrasound and X-ray localization capabilities, the F2
provides unparallel reliability and precision in treatment. With more
than 700 various systems operating worldwide, Karl Storz Lithotripsy
- America, Inc. provides nationwide sales and customer support,
service technicians.
Prescription Dispensing Laboratories, a compounding and research
pharmacy, has developed and patented the use of a calcium channel
blocker (i.e. Transdermal Verapamil 15%) for the non-invasive, transdermal treatment of Peyronie’s disease and other fibrotic connective
tissue disorders.
MCUBE TECHNOLOGY CO., LTD
New York, NY 10017 USA
PFIZER INC
67
235 East 42nd Street
12
Room # 803 Shinnae - Technotown, 485,
Phone: 212-733-2323
Sangboong - Dong, Chungnang-Gu
Web site: www.pfizer.com
Seoul, 131-220 KOREA
Please visit the Pfizer Inc, Worldwide Pharmaceuticals exhibit featuring: TOVIAZ™ (fesoterodine fumarate) extended release tablets 4mg
and 8mg
Phone: 82-2-3421-7780
Web site: www.mcubetech.co.kr
Mcube manufactures and exports Ultrasonic Bladder Scanner[BioCon500] under CE and FDA. BioCon500™ measures volume of remaining urine inside bladder. It’s useful for treatment, surgery, and
rehabilitation in lower urinary tract disorders, due to its non-invasive
method. Decrease in frequency of catheterization reduces rate of urinary tract infection and patients’ pain.
Founded in 1849, Pfizer is the world's largest research-based pharmaceutical company taking new approaches to better health. We
discover, develop, manufacture and deliver quality, safe and effective
prescription medicines to treat and help prevent disease for both
people and animals.
PROUS SCIENCE
OCEANA THERAPEUTICS, INC.
61A
2035 Lincoln Highway, Suite 2150
150 Crows Foot Lane
Centreville, MD 21617 USA
Edison, NJ 08817 USA
Phone: 410-490-0307
Phone: 732-318-3815
Web site: www.prous.com
Web site: www.oceanathera.com
Oceana Therapeutics, Inc. markets and sells Deflux® for the treatment of vesicoureteral reflux (VUR) grades II-IV in children in the
United States.
Please take a moment to discover Oceana Therapeutics at
www.oceanathera.com or visit www.deflux.com.
Timely Topics in Medicine - Urology (www.ttmedurology.com) is a
FREE professional educational Web site for urologists and those
interested in the field of urology. Highlights on the site include
Webcast presentations from the AUA Annual Meeting and AUA
sectional meetings as well as the World Robotic Urology Symposium,
SUFU, FUUS, ISU and EAU.
QDX PATHOLOGY SERVICES
OLYMPUS
81
72
136 Turnpike Road
Cranford, NJ 07016
Southborough, MA 01772 USA
Phone: 1-866-909-PATH
Phone: 508-804-2600
Web Site: www.qdxpath.com
Web site: www.gyrusacmi.com
Olympus and Gyrus ACMI, two of the world’s leading suppliers of
minimally invasive surgical technologies have joined forces to create
a more versatile organization. The best-in-class tissue management
systems of Gyrus ACMI perfectly complement the innovative array of
world-class medical systems and leading-edge opto-digital technology offered by Olympus.
68
46 Jackson Drive
QDx Pathology Services is an independent, CLIA certified, state-ofthe-art pathology company, specializing in anatomic pathology, as
well as cytopathology, and a full range of ancillary services. Our staff
of experienced, board-certified pathologists and cytotechnologists
are dedicated to providing clinicians and patients with diagnostic excellence.
39
Q-MED, INC.
6
504 -703 Evans Avenue, Suite 504
THE CANADIAN JOURNAL OF UROLOGY
1
2330 Ward Street, Suite 604
Toronto, Ontario M9C 5E9 CANADA
St. Laurent, Quebec H4M 2V6 CANADA
Phone: 416-513-1323
Phone: 514-744-1184
Web site: www.q-med.com
Web site: www.canjurol.com
Deflux™, for the paediatric treatment of vesicoureteral reflux (VUR),
is a biocompatible substance manufactured according to Q-Med’s
patented technology of *NASHA, including dextranomer. It is a safe
and effective endoscopic procedure and has been used worldwide to
successfully treat over 50,000 children.
The Canadian Journal of Urology (CJU), is a peer reviewed indexed
urology journal published six times per year. Indexed in Index
Medicus/MEDLINE and Current Contents/Clinical Medicine. Since
its inception in 1994 we have steadily gained recognition in Canada,
United States and the international urological community. We welcome your submissions.
*NASHA = Non-Animal Stabilized Hyaluronic Acid
SANOFI-AVENTIS CANADA, INC.
70
2150 St. Elzear Boulevard W
VISION-SCIENCES, INC
34
40 Ramland Road South
Orangeburg, NY 10962 USA
Laval, Quebec H7L 4A8 CANADA
Phone: 845-365-0600
Phone: 800-265-7927
Web site: www.visionsciences.com
Web site: www.sanofi-aventis.ca
Sanofi-aventis is represented in Canada by the pharmaceutical company sanofi-aventis Canada Inc., based in Laval, Quebec, and by the
vaccines company Sanofi Pasteur Limited, based in Toronto, Ontario.
Together they employ more than 2,000 people and are leaders in
Canada’s biopharmaceutical sector, a critical research-based industry that generates jobs, business and opportunity throughout the
country.
SANOFI-AVENTIS U.S.
76
55 Corporate Drive
Vision-Sciences redefines cystoscopy with its new flexible video cystoscope and sterile, disposable EndoSheath® System. Physicians can
now have revolutionary full screen imaging and advanced endoscopic functionality combined with rapid EndoSheath® turnaround
time, which improves patient throughput. Additionally, EndoSheath®
cystoscopy reduces staff exposure to toxic chemicals, and increases
scope life while minimizing capital, service and maintenance costs.
VIVUS, INC.
17
1172 Castro Street
Mountain View, CA 94040 USA
Bridgewater, NJ 08807 USA
Phone: 650-934-5200
Phone: 908-981-6656
Web site: www.muserx.net
Web site: www.sanofi-aventis.com
Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global
pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is
listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For
more information, visit www.sanofi-aventis.us or www.sanofi-aventis.com.
STAMEN MEDICAL SYSTEMS
61
4811 Technology Drive
VIVUS, Inc. is a pharmaceutical company dedicated to the development and commercialization of next-generation therapeutic products
addressing obesity and sexual health. For more information on clinical trials and products, including MUSE® (alprostadil) urethral suppository and ACTIS® adjustable constriction loop, visit the VIVUS
web site at www.vivus.com.
WATSON PHARMACEUTICALS
23
360 Mt. Kemble Avenue
Morristown, NJ 07960 USA
Martinez, GA 30907 USA
Phone: 973-355-8300
Phone: 706-863-7100
Web site: www.watson.com
Web site: www.stamenmedicalsystems.com
Stamen Medical Systems offers the new Erec-Tech™ and Stamen
Therapy-ED. The Erec-Tech™ is the premier vacuum therapy system.
Erec-Tech’s™ new features will allow patients ease of use as well as
the best treatment results possible with a vacuum therapy system.
We also have the most up to date patient education materials available. Stamen Therapy-ED is a great form of penile rehabilitation for
patients following radical prostatectomy.
Watson is dedicated to improving the lives of affected patients and
advancing the practice of urology in the United States and around
the globe. With developmental therapeutic innovations for BPH and
cystitis, and with current therapeutic innovations for prostate cancer,
overactive bladder (OAB), testosterone replacement, and testicular
hypogonadism function, Watson Urology is committed to meeting the
challenges in urology, today and in the future.
40
Northeastern Section of the AUA — 2009 Annual Meeting
Exhibitor by Booth Number
The Canadian Journal of Urology
Intuitive Surgical, Inc.
Endo Pharmaceuticals
Boston Scientific
Q-Med Inc.
Elsevier Canada
McCube Technology Co., Ltd.
Cook Medical Incorporated
VIVUS, Inc.
Dendreon Corporation
Karl Storz Endoscopy America, Inc
& Karl Storz Lithotripsy
Allergan, Inc.
PD Labs
Watson Pharmaceuticals
Ferring Pharmaceuticals
Vision Sciences, Inc.
Healthtronics, Inc.
Vision-Sciences, Inc
Eli Lilly Canada Inc.
Stamen Medical Systems
Oceana Therapeutics, Inc.
American Medical Systems
1
3
4
5
6
8
12
14
17
18
19
21
22
23
25
34
36
58
60
61
61A
66
Pfizer Inc
QDx Pathology Services
Calmoseptine, Inc.
sanofi-aventis Canada, Inc.
Astellas Pharma Canada, Inc.
Olympus
Coloplast Corp.
sanofi-aventis U.S.
Auxilium Pharmaceuticals, Inc.
Prous Science
67
68
69
70
71
72
73
76
78
81
Get acquainted with fellow Section members and industry partners during the Exhibit Hall
Reception
Enjoy cocktails and hors d'oeuvres
Take a shot at winning a $150
Visa gift card with our hockey game
Thursday, October 8
5:30 –6:30
p.m.
Exhibit Floor Plan
41
Planning Committee/Faculty/Author Disclosures
Abara, Emmanuel O.
Abdo, Al'a
Anidjar, Maurice
Azhar, Raed
Bauer, Ross
Berlach, David M.
Bolduc, Stéphane
Boucher, Andréanne
42
None
None
None
None
None
None
None
Questionnaires and catheters were provided
by Coloplast
Canada Corporation, Commercial Entity,
Other
Budäus, Lars
None
Brock, Gerald B.
Pfizer, Eli Lilly, Coloplast, Bayer and Johnson
and Johnson: Consultant or Advisor
Cardin, Allison L.
None
Carrier, Serge
Pfizer Canada: Board Member, Officer,
Trustee; Bayer Canada: Board Member,
Officer, Trustee; Eli Lilly Canada: Board
Member, Officer, Trustee; Solvay Canada:
Board Member, Officer, Trustee
Chan, Peter
None
Chen, Mang L.
None
Chu, Lei
None
Chughtai, Bilal
None
Cloutier, Jonathan
None
Corcoran, Anthony T.
None
Deschênes Rompré, Marie-Pier None
Deslauriers, Valerie
None
Eassa, Waleed
None
El Sherbiny, Mohamed T.
None
Feuerstein, Michael A.
None
Fisher, Hugh
GTx Inc.: Contracted Research, Commercial
Entity, Other
Fitzpatrick, John M.
None
Gagnon, Louis-Olivier
None
Gayed, Bishoy A.
None
Gingrich, Jeff
GTx Inc,: Clinical Research Investigator,
Commercial Entity, Other
Gordetsky, Jennifer
None
Grober, Ethan D.
None
Guru, Khurshid A.
None
Haidar, Nadim H.
None
Hanna, Nawar
None
Hayn, Matthew
None
Hellenthal, Nicholas
None
Imbeault, Annie
None
Ismail, Salima
None
Izard, Jason
None
Jacobs, Bruce L.
None
Jeldres, Claudio
None
Jolivet-Tremblay, Martine
None
Karakiewicz, Pierre
Abbot Canada: Scientific Study or Trial
Kim, Brian
None
Klein, Eric A.
Abbott Diagnostics: Research Support;
Genomic Health: Research Support
Klotz, Laurence
None
Kotb, Ahmed F.
None
Kovac, Jason
None
Krouchev, Radoslav
None
Kumar, Keshava N.
Watson Laboratories, Inc.: Commercial Entity,
Langillle, Gavin M.
Laroche, Bruno
Larson, Jeff
Lebel, Michel Hugues
Letendre, Julien
Liberman, Daniel
Lorenzo, Armando J.
Lughezzani, Giovanni
Lux, Matthew M.
Luz, Murilo A.
MacLellan, Dawn
Mansure, Jose J.
Mansure, Jose
Maranchie, Jodi K.
Marshall, Jonah S.
McCullough, Andrew R.
Mechlin, Clay W.
Mendez Probst, Carlos E.
Messing, Edward
Moldwin, Robert
Montorsi, Francesco
Nadeau, Geneviève
Nam, Robert K.
Nassim, Roland
Nickel, J. Curtis
O'Flaherty, Cristian
Osman, Yasser
Ouellet, Gabrielle
Rocha, Joice
Rothschild, Jennifer G.
Rutkowski, John M.
Sabaa, Magdy A.
Segal, Robert L.
Siements, D. Robert
Shariat, Shahrokh F.
Singer, Eric A.
Sivalingam, Sri
Smaldone, Marc C.
Su, Ruthie
Sun, Maxine
Szymanski, Konrad M.
Tomaszewski, Jeffrey
Underwood, Willie
Vega, Roger E.
Walker, Adam
Wang, Ching
Yafi, Faysal A.
Yuh, Bertram
Zlotta, Alexandre R.
Employee
None
None
None
None
None
None
None
None
None
None
None
Cancer Research Society: Commercial Entity,
Grant support
CIHR: Commercial Entity, Grant support
None
None
Vivus: Commercial Entity, Grant support
None
None
None
Ortho McNeil Pharmacuiticals: Consultant or
Advisor; Pfizer: Consultant or Advisor,
Investigator; Plethora: Investigator
Pfizer, Bayer, Eli Lilly, Pierre Fabre, American
Medical Systems, Glaxo Smith Klein:
Consultant or Advisor
CUA Abbott: Oncology Prostate Cancer
Research, Commercial Entity, Grant support
None
None
Watson Pharmaceuticals: Commercial Entity,
Consultant, Investigator; Stellar: Investigator,
Commercial Entity, Other
None
None
None
None
None
None
None
None
Sanofi-Aventis: Investigator; Nometics:
Consultant or Advisor; Merk: Investigator
None
None
None
None
None
None
None
None
None
None
None
None
None
None
None
Northeastern Section of the AUA — 2009 Annual Meeting
CME Credit Form
Please fill out and return to the registration counter in registration area at the conclusion of the conference. Or return to the Northeastern Section Administrative Offices at 1000 Corporate Blvd. Linthicum, MD 21090 or fax to 410-689-3837. Only mark those
courses you attend. Your CME certificates will be mailed to the address provided below.
AUA ID# ____________________
LAST NAME
CREDENTIALS
FIRST NAME
ADDRESS
CITY
STATE/PROVINCE
COUNTRY
ZIP/POSTAL CODE
Accreditation
The American Urological Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide
continuing medical education for physicians. The American Urological Association takes responsibility for the content, quality and scientific integrity of this CME activity.
CME Credits
The American Urological Association designates this educational activity for a maximum of 18.75 AMA PRA Category 1 Credits™.
Physicians should only claim credit commensurate with the extent of their participation in the activity
Thursday
7:45 – 8:40 a.m.
8:40 – 9:45 a.m.
10:15 a.m.– Noon
10:15 a.m.– Noon
1:30 – 2 p.m.
2 – 2.45 p.m.
3:15 – 5 p.m.
3:15 – 5 p.m.
____ (1.00 credits)
____ (1.00 credits)
____ (1.75 credits)
____ (1.75 credits)
____ (0.50 credits)
____ (0.75 credits)
____ (1.75 credits)
____ (1.75 credits)
Plenary I: Erectile Dysfunction (ED) After Radical Prostatectomy
Plenary I: Locally Advanced and Metastatic RRC
Moderated Poster Session I: Prostate Cancer
Moderated Poster Session II: Basic Research
Plenary II: Testosterone Supplementation & Its Risks
Plenary II: Prostatitis: A Phoenix Rising
Moderated Poster Session III: Robotics, Endoscopy & Laparoscopy
Moderated Poster Session IV: Bladder Cancer
Thursday Total ____ (6.75 possible)
Friday
7:30 – 7:45 a.m.
7:45 – 8:45 a.m.
8:45 – 9:45 a.m.
9:15 – 9:45 a.m.
10:15 a.m.– Noon
10:15 a.m.– Noon
1:15 – 2:15 p.m.
2:15 – 3:15 p.m.
3:30 – 5 p.m.
3:30 – 5 p.m.
Best of Poster Session
Plenary III: Section Stars
Plenary IV: PSA Screening
State-of-the-Art Lecture 6: New Surgical Concepts for Male Infertility
Moderated Poster Session V: Pediatric Urology
Moderated Poster Session VI: Oncology
Plenary V: Prostate Cancer Chemoprevention
Plenary VI: AUA Course of Choice: Interstitial Cystitis/Painful Bladder
Syndrome and Related Conditions: Practical Management Strategies
Moderated Poster Session VII: General Urology
Moderated Poster Session VIII: Kidney Cancer
____ (0.25 credits)
____ (1.00 credits)
____ (1.00 credits)
____ (0.50 credits)
____ (1.75 credits)
____ (1.75 credits)
____ (1.00 credits)
____ (1.00 credits)
____ (1.50 credits)
____ (1.50 credits)
Friday Total ____ (8.00 possible)
Saturday
7:30 – 8:30 a.m.
8:30 – 8:45 a.m.
8:45 – 9:30 a.m.
9:30 – 10:15 a.m.
10:45 – 11:20 a.m.
11:20 a.m.– Noon
Residents Breakfast Program
Best of Poster Session
George F. Slotkin Lecture: Sun, Light and Shadows
Plenary VI: Androgen Deprivation Therapy
Plenary VII: Urinary Obstruction from the Cradle to the Grave
Plenary VII: Stress Urinary Incontinence and Unstable Bladder
____ (1.00 credits)
____ (0.25 credits)
____ (0.75 credits)
____ (0.75 credits)
____ (0.50 credits)
____ (0.75 credits)
Saturday Total ____ (4.00 possible)
_____________________________________
Signature
OVERALL TOTAL HOURS ____ (Total Possible
Credits 18.75)
Save the Date
Northeastern Section AUA 2010 Annual Meeting
Rich Past, Exciting Present,
and Promising Future on
Three Rivers
Vesicare: Demonstrated Efficacy in
Reducing OAB Symptoms1
Mean change from baseline
OAB SYMPTOM IMPROVEMENT AFTER 12 WEEKS2
0.0
Micturitions/24 hours
Urgency
episodes/24 hours
Urge incontinence
episodes/24 hours
-0.83
-0.5
-1.0
-1.42
-1.5
P=0.001
-2.0
-2.5
-3.0
-2.45
P=0.004
(non-inferiority)
-2.24
Nocturia
episodes/24 hours
-0.71
-0.63
P=0.730
-2.42
-2.85
P=0.035
Vesicare 5 mg/10 mg OD (n=578)
Tolterodine ER 4 mg OD (n=599)
Adapted from Chapple et al., 2005
Prospective, double-blind, double-dummy, two-arm, parallel-group, 12-week trial in OAB patients. Patients were randomized to receive either Vesicare 5 mg OD or
tolterodine ER 4 mg OD. After 4 weeks of treatment, patients had the option to request a dose increase but were dummied throughout as product labelling only
allowed an increase for those on Vesicare from 5 mg to 10 mg OD.
Vesicare demonstrated a greater reduction in urgency and urge
incontinence episodes from baseline than tolterodine ER2
U Urgency: -47% (-2.85) Vesicare vs -41% (-2.42) tolterodine ER
U Urge incontinence: -61% (-1.42) Vesicare vs -39% (-0.83) tolterodine ER
INDICATIONS: Vesicare (solifenacin succinate) is indicated for the
treatment of overactive bladder in adults with symptoms of urge
urinary incontinence, urinary urgency and urinary frequency.
Safety and effectiveness in children have not yet been established.
CONTRAINDICATIONS: Patients with urinary retention, dependent
on dialysis, gastroparesis or narrow angle glaucoma. Patients
who are hypersensitive to this drug or to any ingredient in the
formulation or component of the container.
Women of childbearing potential should be considered for treatment
only if using adequate contraception.
ADVERSE EVENTS: Expected side effects of antimuscarinic agents
are dry mouth, constipation, blurred vision (accommodation
abnormalities), urinary retention, and dry eyes. The most common
adverse events reported in patients treated with Vesicare were dry
mouth and constipation and the incidence of these side effects was
higher in the 10 mg (27.6% and 13.4%, respectively) compared to
the 5 mg (10.9% and 5.4%, respectively) dose group (4.2% and 2.9%
for placebo, respectively).
References: 1. Vesicare Product Monograph, Astellas Pharma Canada. Inc. 2008. 2. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of
the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results from the STAR trial.
Eur Urol 2005;48:464-470.
Helps Control Urgency
Vesicare
Help your Overactive Bladder patients
with the discomfort of urgency.
`